ID   INSR_HUMAN              Reviewed;        1382 AA.
AC   P06213; Q17RW0; Q59H98; Q9UCB7; Q9UCB8; Q9UCB9;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 4.
DT   12-OCT-2022, entry version 278.
DE   RecName: Full=Insulin receptor;
DE            Short=IR;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD220;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit alpha;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit beta;
DE   Flags: Precursor;
GN   Name=INSR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANTS GLY-2; HIS-171;
RP   THR-448 AND LYS-492.
RX   PubMed=2859121; DOI=10.1016/0092-8674(85)90334-4;
RA   Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E., Ou J.-H.,
RA   Masiarz F., Kan Y.W., Goldfine I.D., Roth R.A., Rutter W.J.;
RT   "The human insulin receptor cDNA: the structural basis for hormone-
RT   activated transmembrane signalling.";
RL   Cell 40:747-758(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), PROTEIN SEQUENCE OF 28-49 AND
RP   763-782, GLYCOSYLATION AT ASN-43 AND ASN-769, AND VARIANT GLY-2.
RX   PubMed=2983222; DOI=10.1038/313756a0;
RA   Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M., Dull T.J.,
RA   Gray A., Coussens L., Liao Y.-C., Tsubokawa M., Mason A., Seeburg P.H.,
RA   Grunfeld C., Rosen O.M., Ramachandran J.;
RT   "Human insulin receptor and its relationship to the tyrosine kinase family
RT   of oncogenes.";
RL   Nature 313:756-761(1985).
RN   [3]
RP   SEQUENCE REVISION TO 899-900.
RA   Chen E.Y.;
RL   Submitted (JUL-1985) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-2.
RC   TISSUE=Fetal liver;
RX   PubMed=2210055; DOI=10.2337/diacare.39.1.123;
RA   Seino S., Seino M., Bell G.I.;
RT   "Human insulin-receptor gene. Partial sequence and amplification of exons
RT   by polymerase chain reaction.";
RL   Diabetes 39:123-128(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT), AND VARIANT GLY-2.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   PubMed=3680248; DOI=10.1016/s0021-9258(18)47714-9;
RA   Araki E., Shimada F., Uzawa H., Mori M., Ebina Y.;
RT   "Characterization of the promoter region of the human insulin receptor
RT   gene. Evidence for promoter activity.";
RL   J. Biol. Chem. 262:16186-16191(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   PubMed=2806055; DOI=10.1016/0168-8227(89)90085-5;
RA   Araki E., Shimada F., Fukushima H., Mori M., Shichiri M., Ebina Y.;
RT   "Characterization of the promoter region of the human insulin receptor
RT   gene.";
RL   Diabetes Res. Clin. Pract. 7:S31-S33(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   PubMed=2777789; DOI=10.1016/s0021-9258(18)71612-8;
RA   Tewari D.S., Cook D.M., Taub R.;
RT   "Characterization of the promoter region and 3' end of the human insulin
RT   receptor gene.";
RL   J. Biol. Chem. 264:16238-16245(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RC   TISSUE=Skin fibroblast;
RX   PubMed=2280779; DOI=10.1210/mend-4-4-647;
RA   McKeon C., Moncada V., Pham T., Salvatore P., Kadowaki T., Accili D.,
RA   Taylor S.I.;
RT   "Structural and functional analysis of the insulin receptor promoter.";
RL   Mol. Endocrinol. 4:647-656(1990).
RN   [11]
RP   PROTEIN SEQUENCE OF 28-44; 192-205; 299-314; 610-627 AND 763-780, ACTIVITY
RP   REGULATION, AND SUBUNIT.
RC   TISSUE=Placenta;
RX   PubMed=2211730; DOI=10.1016/s0021-9258(17)44805-8;
RA   Xu Q.-Y., Paxton R.J., Fujita-Yamaguchi Y.;
RT   "Substructural analysis of the insulin receptor by microsequence analyses
RT   of limited tryptic fragments isolated by sodium dodecyl sulfate-
RT   polyacrylamide gel electrophoresis in the absence or presence of
RT   dithiothreitol.";
RL   J. Biol. Chem. 265:18673-18681(1990).
RN   [12]
RP   PROTEIN SEQUENCE OF 28-45 AND 763-782, FUNCTION, AND FORMATION OF A HYBRID
RP   RECEPTOR WITH IGF1R.
RC   TISSUE=Placenta;
RX   PubMed=8257688; DOI=10.1021/bi00212a019;
RA   Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A.,
RA   Fujita-Yamaguchi Y.;
RT   "Characterization of human placental insulin-like growth factor-I/insulin
RT   hybrid receptors by protein microsequencing and purification.";
RL   Biochemistry 32:13531-13536(1993).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 538-1382 (ISOFORM SHORT).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 728-772 (ISOFORM LONG), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=2538124; DOI=10.1016/0006-291x(89)92439-x;
RA   Seino S., Bell G.I.;
RT   "Alternative splicing of human insulin receptor messenger RNA.";
RL   Biochem. Biophys. Res. Commun. 159:312-316(1989).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 744-823 (ISOFORM LONG), TISSUE SPECIFICITY,
RP   LIGAND-BINDING, AND AUTOPHOSPHORYLATION.
RX   PubMed=2369896; DOI=10.1002/j.1460-2075.1990.tb07416.x;
RA   Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A., McClain D.A.;
RT   "Functionally distinct insulin receptors generated by tissue-specific
RT   alternative splicing.";
RL   EMBO J. 9:2409-2413(1990).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 895-1085.
RX   PubMed=2566545; DOI=10.2337/diab.38.6.737;
RA   Elbein S.C.;
RT   "Molecular and clinical characterization of an insertional polymorphism of
RT   the insulin-receptor gene.";
RL   Diabetes 38:737-743(1989).
RN   [17]
RP   PROTEIN SEQUENCE OF 927-956; 981-1019; 1182-1194 AND 1352-1369, AND
RP   PHOSPHORYLATION AT TYR-999; TYR-1355 AND TYR-1361.
RC   TISSUE=Placenta;
RX   PubMed=3166375; DOI=10.1042/bj2520607;
RA   Tavare J.M., Denton R.M.;
RT   "Studies on the autophosphorylation of the insulin receptor from human
RT   placenta. Analysis of the sites phosphorylated by two-dimensional peptide
RT   mapping.";
RL   Biochem. J. 252:607-615(1988).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1006-1123.
RX   PubMed=2544997; DOI=10.1126/science.2544997;
RA   Taira M., Taira M., Hashimoto N., Shimada F., Suzuki Y., Kanatsuka A.,
RA   Nakamura F., Ebina Y., Tatibana M., Makino H.;
RT   "Human diabetes associated with a deletion of the tyrosine kinase domain of
RT   the insulin receptor.";
RL   Science 245:63-66(1989).
RN   [19]
RP   PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3447155;
RA   Fujita-Yamaguchi Y., Hawke D., Shively J.E., Choi S.;
RT   "Partial amino acid sequence analyses of human placental insulin
RT   receptor.";
RL   Protein Seq. Data Anal. 1:3-6(1987).
RN   [20]
RP   MUTAGENESIS OF LYS-1057.
RX   PubMed=3101064; DOI=10.1073/pnas.84.3.704;
RA   Ebina Y., Araki E., Taira M., Shimada F., Mori M., Craik C.S., Siddle K.,
RA   Pierce S.B., Roth R.A., Rutter W.J.;
RT   "Replacement of lysine residue 1030 in the putative ATP-binding region of
RT   the insulin receptor abolishes insulin- and antibody-stimulated glucose
RT   uptake and receptor kinase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:704-708(1987).
RN   [21]
RP   MUTAGENESIS OF TYR-999.
RX   PubMed=2842060; DOI=10.1016/s0092-8674(88)80008-4;
RA   White M.F., Livingston J.N., Backer J.M., Lauris V., Dull T.J., Ullrich A.,
RA   Kahn C.R.;
RT   "Mutation of the insulin receptor at tyrosine 960 inhibits signal
RT   transmission but does not affect its tyrosine kinase activity.";
RL   Cell 54:641-649(1988).
RN   [22]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=1321605; DOI=10.1016/s0006-291x(05)80799-5;
RA   Dickens M., Tavare J.M.;
RT   "Analysis of the order of autophosphorylation of human insulin receptor
RT   tyrosines 1158, 1162 and 1163.";
RL   Biochem. Biophys. Res. Commun. 186:244-250(1992).
RN   [23]
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-541.
RX   PubMed=1472036; DOI=10.1016/0006-291x(92)92250-2;
RA   Schaeffer L., Ljungqvist L.;
RT   "Identification of a disulfide bridge connecting the alpha-subunits of the
RT   extracellular domain of the insulin receptor.";
RL   Biochem. Biophys. Res. Commun. 189:650-653(1992).
RN   [24]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=8452530; DOI=10.1042/bj2900419;
RA   Soos M.A., Field C.E., Siddle K.;
RT   "Purified hybrid insulin/insulin-like growth factor-I receptors bind
RT   insulin-like growth factor-I, but not insulin, with high affinity.";
RL   Biochem. J. 290:419-426(1993).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH PIK3R1.
RX   PubMed=8276809; DOI=10.1016/s0021-9258(17)42304-0;
RA   Van Horn D.J., Myers M.G. Jr., Backer J.M.;
RT   "Direct activation of the phosphatidylinositol 3'-kinase by the insulin
RT   receptor.";
RL   J. Biol. Chem. 269:29-32(1994).
RN   [26]
RP   INTERACTION WITH IRS1 AND SHC1, AND MUTAGENESIS OF LEU-991; TYR-992;
RP   ASN-996; 996-ASN-PRO-997; PRO-997; TYR-999; LEU-1000 AND ALA-1002.
RX   PubMed=7559478; DOI=10.1074/jbc.270.40.23258;
RA   He W., O'Neill T.J., Gustafson T.A.;
RT   "Distinct modes of interaction of SHC and insulin receptor substrate-1 with
RT   the insulin receptor NPEY region via non-SH2 domains.";
RL   J. Biol. Chem. 270:23258-23262(1995).
RN   [27]
RP   INTERACTION WITH IRS1; SHC1 AND PIK3R1, AND MUTAGENESIS OF ASN-996;
RP   PRO-997; GLU-998; TYR-999 AND LYS-1057.
RX   PubMed=7537849; DOI=10.1128/mcb.15.5.2500;
RA   Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.;
RT   "Phosphotyrosine-dependent interaction of SHC and insulin receptor
RT   substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2
RT   domain.";
RL   Mol. Cell. Biol. 15:2500-2508(1995).
RN   [28]
RP   FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY.
RX   PubMed=9355755; DOI=10.1042/bj3270209;
RA   Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.;
RT   "Insulin receptor/IGF-I receptor hybrids are widely distributed in
RT   mammalian tissues: quantification of individual receptor species by
RT   selective immunoprecipitation and immunoblotting.";
RL   Biochem. J. 327:209-215(1997).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF STAT5B, MUTAGENESIS OF TYR-999, AND
RP   INTERACTION WITH STAT5B; IRS1 AND IRS2.
RX   PubMed=9428692; DOI=10.1111/j.1432-1033.1997.0411a.x;
RA   Sawka-Verhelle D., Filloux C., Tartare-Deckert S., Mothe I.,
RA   Van Obberghen E.;
RT   "Identification of Stat 5B as a substrate of the insulin receptor.";
RL   Eur. J. Biochem. 250:411-417(1997).
RN   [30]
RP   INTERACTION WITH PTPRF.
RX   PubMed=8995282; DOI=10.1074/jbc.272.11.7519;
RA   Ahmad F., Goldstein B.J.;
RT   "Functional association between the insulin receptor and the transmembrane
RT   protein-tyrosine phosphatase LAR in intact cells.";
RL   J. Biol. Chem. 272:448-457(1997).
RN   [31]
RP   INTERACTION WITH PTPRE, AND DEPHOSPHORYLATION BY PTPRE.
RX   PubMed=8999839; DOI=10.1074/jbc.272.3.1639;
RA   Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J.,
RA   Gustafson T.A., Kusari J.;
RT   "Protein-tyrosine phosphatase 1B complexes with the insulin receptor in
RT   vivo and is tyrosine-phosphorylated in the presence of insulin.";
RL   J. Biol. Chem. 272:1639-1645(1997).
RN   [32]
RP   FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY.
RX   PubMed=9202395; DOI=10.1016/s0303-7207(97)04050-1;
RA   Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D.,
RA   Sesti G.;
RT   "Distribution of insulin/insulin-like growth factor-I hybrid receptors in
RT   human tissues.";
RL   Mol. Cell. Endocrinol. 129:121-126(1997).
RN   [33]
RP   TISSUE SPECIFICITY, AND FUNCTION AS RECEPTOR FOR IGFII (ISOFORM SHORT).
RX   PubMed=10207053; DOI=10.1128/mcb.19.5.3278;
RA   Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A.,
RA   Goldfine I.D., Belfiore A., Vigneri R.;
RT   "Insulin receptor isoform A, a newly recognized, high-affinity insulin-like
RT   growth factor II receptor in fetal and cancer cells.";
RL   Mol. Cell. Biol. 19:3278-3288(1999).
RN   [34]
RP   INTERACTION WITH ENPP1, AND ACTIVITY REGULATION.
RX   PubMed=10615944; DOI=10.2337/diabetes.49.1.13;
RA   Maddux B.A., Goldfine I.D.;
RT   "Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs
RT   via direct interaction with the receptor alpha-subunit.";
RL   Diabetes 49:13-19(2000).
RN   [35]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2.
RX   PubMed=10734133; DOI=10.1074/jbc.275.13.9792;
RA   Waelchli S., Curchod M.L., Gobert R.P., Arkinstall S.,
RA   Hooft van Huijsduijnen R.;
RT   "Identification of tyrosine phosphatases that dephosphorylate the insulin
RT   receptor. A brute force approach based on 'substrate-trapping' mutants.";
RL   J. Biol. Chem. 275:9792-9796(2000).
RN   [36]
RP   INTERACTION WITH GRB7, AND MUTAGENESIS OF LYS-1057; TYR-1189 AND TYR-1190.
RX   PubMed=10803466; DOI=10.1038/sj.onc.1203469;
RA   Kasus-Jacobi A., Bereziat V., Perdereau D., Girard J., Burnol A.F.;
RT   "Evidence for an interaction between the insulin receptor and Grb7. A role
RT   for two of its binding domains, PIR and SH2.";
RL   Oncogene 19:2052-2059(2000).
RN   [37]
RP   INTERACTION WITH SORBS1.
RX   PubMed=11374898; DOI=10.1006/geno.2001.6541;
RA   Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y.,
RA   Chuang L.-M.;
RT   "Cloning, mapping, and characterization of the human sorbin and SH3 domain
RT   containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin
RT   signaling in the hepatoma cell line Hep3B.";
RL   Genomics 74:12-20(2001).
RN   [38]
RP   CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-1159 AND ARG-1163, AND ACTIVITY
RP   REGULATION.
RX   PubMed=11598120; DOI=10.1074/jbc.m107236200;
RA   Ablooglu A.J., Frankel M., Rusinova E., Ross J.B., Kohanski R.A.;
RT   "Multiple activation loop conformations and their regulatory properties in
RT   the insulin receptor's kinase domain.";
RL   J. Biol. Chem. 276:46933-46940(2001).
RN   [39]
RP   INTERACTION WITH GRB14, AND ACTIVITY REGULATION.
RX   PubMed=11726652; DOI=10.1074/jbc.m106574200;
RA   Bereziat V., Kasus-Jacobi A., Perdereau D., Cariou B., Girard J.,
RA   Burnol A.F.;
RT   "Inhibition of insulin receptor catalytic activity by the molecular adapter
RT   Grb14.";
RL   J. Biol. Chem. 277:4845-4852(2002).
RN   [40]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=12138094; DOI=10.1074/jbc.m202766200;
RA   Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.;
RT   "Insulin/insulin-like growth factor I hybrid receptors have different
RT   biological characteristics depending on the insulin receptor isoform
RT   involved.";
RL   J. Biol. Chem. 277:39684-39695(2002).
RN   [41]
RP   INTERACTION WITH GRB10, AND ACTIVITY REGULATION.
RX   PubMed=12493740; DOI=10.1074/jbc.m208518200;
RA   Wick K.R., Werner E.D., Langlais P., Ramos F.J., Dong L.Q., Shoelson S.E.,
RA   Liu F.;
RT   "Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-
RT   phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the
RT   association of IRS-1/IRS-2 with the insulin receptor.";
RL   J. Biol. Chem. 278:8460-8467(2003).
RN   [42]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2.
RX   PubMed=12612081; DOI=10.1128/mcb.23.6.2096-2108.2003;
RA   Galic S., Klingler-Hoffmann M., Fodero-Tavoletti M.T., Puryer M.A.,
RA   Meng T.C., Tonks N.K., Tiganis T.;
RT   "Regulation of insulin receptor signaling by the protein tyrosine
RT   phosphatase TCPTP.";
RL   Mol. Cell. Biol. 23:2096-2108(2003).
RN   [43]
RP   INTERACTION WITH SOCS7.
RX   PubMed=16127460; DOI=10.1172/jci23853;
RA   Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D.,
RA   Rothman P.B.;
RT   "Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of
RT   Langerhans.";
RL   J. Clin. Invest. 115:2462-2471(2005).
RN   [44]
RP   FUNCTION IN PHOSPHORYLATION OF PDPK1, AND INTERACTION WITH PDPK1.
RX   PubMed=16314505; DOI=10.1128/mcb.25.24.10803-10814.2005;
RA   Fiory F., Alberobello A.T., Miele C., Oriente F., Esposito I., Corbo V.,
RA   Ruvo M., Tizzano B., Rasmussen T.E., Gammeltoft S., Formisano P.,
RA   Beguinot F.;
RT   "Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the
RT   insulin receptor is necessary for insulin metabolic signaling.";
RL   Mol. Cell. Biol. 25:10803-10814(2005).
RN   [45]
RP   DEPHOSPHORYLATION BY PTPRE.
RX   PubMed=15738637; DOI=10.2108/zsj.22.169;
RA   Nakagawa Y., Aoki N., Aoyama K., Shimizu H., Shimano H., Yamada N.,
RA   Miyazaki H.;
RT   "Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a
RT   negative regulator of insulin signaling in primary hepatocytes and liver.";
RL   Zool. Sci. 22:169-175(2005).
RN   [46]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=16831875; DOI=10.1074/jbc.m605189200;
RA   Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C.,
RA   Mathiasen I.S., Brandt J.;
RT   "Hybrid receptors formed by insulin receptor (IR) and insulin-like growth
RT   factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity
RT   irrespective of the IR splice variant.";
RL   J. Biol. Chem. 281:25869-25874(2006).
RN   [47]
RP   REVIEW ON SIGNALING PATHWAYS.
RX   PubMed=16493415; DOI=10.1038/nrm1837;
RA   Taniguchi C.M., Emanuelli B., Kahn C.R.;
RT   "Critical nodes in signalling pathways: insights into insulin action.";
RL   Nat. Rev. Mol. Cell Biol. 7:85-96(2006).
RN   [48]
RP   REVIEW ON REGULATION OF INSR FUNCTION.
RX   PubMed=17347799; DOI=10.1007/s00018-007-6359-9;
RA   Youngren J.F.;
RT   "Regulation of insulin receptor function.";
RL   Cell. Mol. Life Sci. 64:873-891(2007).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-400; TYR-401 AND SER-407, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [50]
RP   DOMAIN, AND INSULIN-BINDING SITE.
RX   PubMed=19459609; DOI=10.1021/bi900261q;
RA   Menting J.G., Ward C.W., Margetts M.B., Lawrence M.C.;
RT   "A thermodynamic study of ligand binding to the first three domains of the
RT   human insulin receptor: relationship between the receptor alpha-chain C-
RT   terminal peptide and the site 1 insulin mimetic peptides.";
RL   Biochemistry 48:5492-5500(2009).
RN   [51]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-242 AND ASN-541.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [52]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [53]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445 AND ASN-920.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [54]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [55]
RP   INTERACTION WITH CCDC88A AND GNAI3.
RX   PubMed=25187647; DOI=10.1091/mbc.e14-05-0978;
RA   Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M.,
RA   Kufareva I., Abagyan R., Ghosh P.;
RT   "Structural basis for activation of trimeric Gi proteins by multiple growth
RT   factor receptors via GIV/Girdin.";
RL   Mol. Biol. Cell 25:3654-3671(2014).
RN   [56]
RP   INTERACTION WITH SORL1.
RX   PubMed=27322061; DOI=10.1172/jci84708;
RA   Schmidt V., Schulz N., Yan X., Schuermann A., Kempa S., Kern M.,
RA   Blueher M., Poy M.N., Olivecrona G., Willnow T.E.;
RT   "SORLA facilitates insulin receptor signaling in adipocytes and exacerbates
RT   obesity.";
RL   J. Clin. Invest. 126:2706-2720(2016).
RN   [57]
RP   SUBUNIT.
RX   PubMed=27617429; DOI=10.1038/nsmb.3292;
RA   Menting J.G., Gajewiak J., MacRaild C.A., Chou D.H., Disotuar M.M.,
RA   Smith N.A., Miller C., Erchegyi J., Rivier J.E., Olivera B.M., Forbes B.E.,
RA   Smith B.J., Norton R.S., Safavi-Hemami H., Lawrence M.C.;
RT   "A minimized human insulin-receptor-binding motif revealed in a Conus
RT   geographus venom insulin.";
RL   Nat. Struct. Mol. Biol. 23:916-920(2016).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310.
RX   PubMed=7997262; DOI=10.1038/372746a0;
RA   Hubbard S.R., Wei L., Ellis L., Hendrickson W.A.;
RT   "Crystal structure of the tyrosine kinase domain of the human insulin
RT   receptor.";
RL   Nature 372:746-754(1994).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP
RP   ANALOG AND IRS1 PEPTIDE, CATALYTIC ACTIVITY, ACTIVE SITE,
RP   AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND
RP   TYR-1190.
RX   PubMed=9312016; DOI=10.1093/emboj/16.18.5572;
RA   Hubbard S.R.;
RT   "Crystal structure of the activated insulin receptor tyrosine kinase in
RT   complex with peptide substrate and ATP analog.";
RL   EMBO J. 16:5572-5581(1997).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP
RP   ANALOG, AND CATALYTIC ACTIVITY.
RX   PubMed=11124964; DOI=10.1074/jbc.m010161200;
RA   Till J.H., Ablooglu A.J., Frankel M., Bishop S.M., Kohanski R.A.,
RA   Hubbard S.R.;
RT   "Crystallographic and solution studies of an activation loop mutant of the
RT   insulin receptor tyrosine kinase: insights into kinase mechanism.";
RL   J. Biol. Chem. 276:10049-10055(2001).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1298 OF MUTANT ASN-1159,
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF TYR-1011.
RX   PubMed=12707268; DOI=10.1074/jbc.m302425200;
RA   Li S., Covino N.D., Stein E.G., Till J.H., Hubbard S.R.;
RT   "Structural and biochemical evidence for an autoinhibitory role for
RT   tyrosine 984 in the juxtamembrane region of the insulin receptor.";
RL   J. Biol. Chem. 278:26007-26014(2003).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP
RP   ANALOG AND SH2B2, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190.
RX   PubMed=14690593; DOI=10.1016/s1097-2765(03)00487-8;
RA   Hu J., Liu J., Ghirlando R., Saltiel A.R., Hubbard S.R.;
RT   "Structural basis for recruitment of the adaptor protein APS to the
RT   activated insulin receptor.";
RL   Mol. Cell 12:1379-1389(2003).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH GRB14,
RP   INTERACTION WITH GRB14, AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT
RP   TYR-1185; TYR-1189 AND TYR-1190.
RX   PubMed=16246733; DOI=10.1016/j.molcel.2005.09.001;
RA   Depetris R.S., Hu J., Gimpelevich I., Holt L.J., Daly R.J., Hubbard S.R.;
RT   "Structural basis for inhibition of the insulin receptor by the adaptor
RT   protein Grb14.";
RL   Mol. Cell 20:325-333(2005).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH PTPN1,
RP   AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190.
RX   PubMed=16271887; DOI=10.1016/j.str.2005.07.019;
RA   Li S., Depetris R.S., Barford D., Chernoff J., Hubbard S.R.;
RT   "Crystal structure of a complex between protein tyrosine phosphatase 1B and
RT   the insulin receptor tyrosine kinase.";
RL   Structure 13:1643-1651(2005).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS) OF 28-943 IN COMPLEX WITH INSULIN
RP   ANALOG, DOMAIN, AND DISULFIDE BONDS.
RX   PubMed=16957736; DOI=10.1038/nature05106;
RA   McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E.,
RA   Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A.,
RA   Hoyne P.A., Cartledge K.A., Pham T.M., Lewis J.L., Sankovich S.E.,
RA   Stoichevska V., Da Silva E., Robinson C.P., Frenkel M.J., Sparrow L.G.,
RA   Fernley R.T., Epa V.C., Ward C.W.;
RT   "Structure of the insulin receptor ectodomain reveals a folded-over
RT   conformation.";
RL   Nature 443:218-221(2006).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 28-512, GLYCOSYLATION AT ASN-43;
RP   ASN-52; ASN-138; ASN-242; ASN-282; ASN-364; ASN-424 AND ASN-445, AND
RP   DISULFIDE BONDS.
RX   PubMed=16894147; DOI=10.1073/pnas.0605395103;
RA   Lou M., Garrett T.P., McKern N.M., Hoyne P.A., Epa V.C., Bentley J.D.,
RA   Lovrecz G.O., Cosgrove L.J., Frenkel M.J., Ward C.W.;
RT   "The first three domains of the insulin receptor differ structurally from
RT   the insulin-like growth factor 1 receptor in the regions governing ligand
RT   specificity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:12429-12434(2006).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP AND
RP   IRS2, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-1185; TYR-1189 AND
RP   TYR-1190, AND INTERACTION WITH IRS2.
RX   PubMed=18278056; DOI=10.1038/nsmb.1388;
RA   Wu J., Tseng Y.D., Xu C.F., Neubert T.A., White M.F., Hubbard S.R.;
RT   "Structural and biochemical characterization of the KRLB region in insulin
RT   receptor substrate-2.";
RL   Nat. Struct. Mol. Biol. 15:251-258(2008).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1009-1310 IN COMPLEX WITH
RP   INHIBITORY PEPTIDE, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190.
RX   PubMed=18767165; DOI=10.1002/prot.22207;
RA   Katayama N., Orita M., Yamaguchi T., Hisamichi H., Kuromitsu S.,
RA   Kurihara H., Sakashita H., Matsumoto Y., Fujita S., Niimi T.;
RT   "Identification of a key element for hydrogen-bonding patterns between
RT   protein kinases and their inhibitors.";
RL   Proteins 73:795-801(2008).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19071018; DOI=10.1016/j.bmcl.2008.11.077;
RA   Chamberlain S.D., Redman A.M., Wilson J.W., Deanda F., Shotwell J.B.,
RA   Gerding R., Lei H., Yang B., Stevens K.L., Hassell A.M., Shewchuk L.M.,
RA   Leesnitzer M.A., Smith J.L., Sabbatini P., Atkins C., Groy A., Rowand J.L.,
RA   Kumar R., Mook R.A. Jr., Moorthy G., Patnaik S.;
RT   "Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R
RT   tyrosine kinase inhibitors towards JNK selectivity.";
RL   Bioorg. Med. Chem. Lett. 19:360-364(2009).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19056263; DOI=10.1016/j.bmcl.2008.11.046;
RA   Chamberlain S.D., Wilson J.W., Deanda F., Patnaik S., Redman A.M., Yang B.,
RA   Shewchuk L., Sabbatini P., Leesnitzer M.A., Groy A., Atkins C., Gerding R.,
RA   Hassell A.M., Lei H., Mook R.A. Jr., Moorthy G., Rowand J.L., Stevens K.L.,
RA   Kumar R., Shotwell J.B.;
RT   "Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent
RT   inhibitors of the IGF-1R receptor tyrosine kinase.";
RL   Bioorg. Med. Chem. Lett. 19:469-473(2009).
RN   [71]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1017-1322 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19394223; DOI=10.1016/j.bmcl.2008.12.110;
RA   Patnaik S., Stevens K.L., Gerding R., Deanda F., Shotwell J.B., Tang J.,
RA   Hamajima T., Nakamura H., Leesnitzer M.A., Hassell A.M., Shewchuck L.M.,
RA   Kumar R., Lei H., Chamberlain S.D.;
RT   "Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent
RT   inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine
RT   kinase.";
RL   Bioorg. Med. Chem. Lett. 19:3136-3140(2009).
RN   [72]
RP   X-RAY CRYSTALLOGRAPHY (3.80 ANGSTROMS) OF 28-956, INSULIN-BINDING REGION,
RP   AND DISULFIDE BONDS.
RX   PubMed=20348418; DOI=10.1073/pnas.1001813107;
RA   Smith B.J., Huang K., Kong G., Chan S.J., Nakagawa S., Menting J.G.,
RA   Hu S.Q., Whittaker J., Steiner D.F., Katsoyannis P.G., Ward C.W.,
RA   Weiss M.A., Lawrence M.C.;
RT   "Structural resolution of a tandem hormone-binding element in the insulin
RT   receptor and its implications for design of peptide agonists.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:6771-6776(2010).
RN   [73]
RP   X-RAY CRYSTALLOGRAPHY (3.9 ANGSTROMS) OF 28-620 IN COMPLEX WITH INSULIN,
RP   DOMAIN, GLYCOSYLATION AT ASN-43; ASN-52; ASN-138; ASN-242 AND ASN-282, AND
RP   DISULFIDE BONDS.
RX   PubMed=23302862; DOI=10.1038/nature11781;
RA   Menting J.G., Whittaker J., Margetts M.B., Whittaker L.J., Kong G.K.,
RA   Smith B.J., Watson C.J., Zakova L., Kletvikova E., Jiracek J., Chan S.J.,
RA   Steiner D.F., Dodson G.G., Brzozowski A.M., Weiss M.A., Ward C.W.,
RA   Lawrence M.C.;
RT   "How insulin engages its primary binding site on the insulin receptor.";
RL   Nature 493:241-245(2013).
RN   [74]
RP   VARIANT IRAN TYPE A SER-762.
RX   PubMed=3283938; DOI=10.1126/science.3283938;
RA   Yoshimasa Y., Seino S., Whittaker J., Kakehi T., Kosaki A., Kuzuya H.,
RA   Imura H., Bell G.I., Steiner D.F.;
RT   "Insulin-resistant diabetes due to a point mutation that prevents insulin
RT   proreceptor processing.";
RL   Science 240:784-787(1988).
RN   [75]
RP   VARIANT LEPRCH GLU-487.
RX   PubMed=2834824; DOI=10.1126/science.2834824;
RA   Kadowaki T., Bevins C., Cama A., Ojamaa K., Marcus-Samuels B., Kadowaki H.,
RA   Beitz L., McKeon C., Taylor S.I.;
RT   "Two mutant alleles of the insulin receptor gene in a patient with extreme
RT   insulin resistance.";
RL   Science 240:787-790(1988).
RN   [76]
RP   VARIANT LEPRCH PRO-260.
RX   PubMed=2479553; DOI=10.1002/j.1460-2075.1989.tb08387.x;
RA   Klinkhamer M.P., Groen N.A., van der Zon G.C.M., Lindhout D.,
RA   Sandkuyl L.A., Krans H.M.J., Moeller W., Maassen J.A.;
RT   "A leucine-to-proline mutation in the insulin receptor in a family with
RT   insulin resistance.";
RL   EMBO J. 8:2503-2507(1989).
RN   [77]
RP   VARIANT IRAN TYPE A VAL-1035.
RX   PubMed=2544998; DOI=10.1126/science.2544998;
RA   Odawara M., Kadowaki T., Yamamoto R., Shibasaki Y., Tobe K., Accili D.,
RA   Bevins C., Mikami Y., Matsuura N., Akanuma Y., Takaku F., Taylor S.I.,
RA   Kasuga M.;
RT   "Human diabetes associated with a mutation in the tyrosine kinase domain of
RT   the insulin receptor.";
RL   Science 245:66-68(1989).
RN   [78]
RP   VARIANT IRAN TYPE A THR-1161.
RX   PubMed=2168397; DOI=10.1016/s0021-9258(18)77212-8;
RA   Moller D.E., Yokota A., White M.F., Pazianos A.G., Flier J.S.;
RT   "A naturally occurring mutation of insulin receptor alanine 1134 impairs
RT   tyrosine kinase function and is associated with dominantly inherited
RT   insulin resistance.";
RL   J. Biol. Chem. 265:14979-14985(1990).
RN   [79]
RP   CHARACTERIZATION OF VARIANT RMS LYS-42.
RX   PubMed=2121734; DOI=10.1016/s0021-9258(17)30636-1;
RA   Kadowaki T., Kadowaki H., Accili D., Taylor S.I.;
RT   "Substitution of lysine for asparagine at position 15 in the alpha-subunit
RT   of the human insulin receptor. A mutation that impairs transport of
RT   receptors to the cell surface and decreases the affinity of insulin
RT   binding.";
RL   J. Biol. Chem. 265:19143-19150(1990).
RN   [80]
RP   VARIANT RMS LYS-42, VARIANT LEPRCH ARG-236, AND VARIANT IRAN TYPE A
RP   SER-489.
RX   PubMed=2365819; DOI=10.1172/jci114693;
RA   Kadowaki T., Kadowaki H., Rechler M.M., Serrano-Rios M., Roth J.,
RA   Gorden P., Taylor S.I.;
RT   "Five mutant alleles of the insulin receptor gene in patients with genetic
RT   forms of insulin resistance.";
RL   J. Clin. Invest. 86:254-264(1990).
RN   [81]
RP   VARIANT IRAN TYPE A SER-1227.
RX   PubMed=1963473; DOI=10.1210/mend-4-8-1183;
RA   Moller D.E., Yokota A., Ginsberg-Fellner F., Flier J.S.;
RT   "Functional properties of a naturally occurring Trp1200-->Ser1200 mutation
RT   of the insulin receptor.";
RL   Mol. Endocrinol. 4:1183-1191(1990).
RN   [82]
RP   VARIANT GLU-1095.
RX   PubMed=2040394; DOI=10.2337/diab.40.6.777;
RA   O'Rahilly S., Choi W.H., Patel P., Turner R.C., Flier J.S., Moller D.E.;
RT   "Detection of mutations in insulin-receptor gene in NIDDM patients by
RT   analysis of single-stranded conformation polymorphisms.";
RL   Diabetes 40:777-782(1991).
RN   [83]
RP   VARIANT IRAN TYPE A GLN-1020.
RX   PubMed=2002058; DOI=10.1016/s0021-9258(19)67781-1;
RA   Kusari J., Takata Y., Hatada E., Freidenberg G., Kolterman O.,
RA   Olefsky J.M.;
RT   "Insulin resistance and diabetes due to different mutations in the tyrosine
RT   kinase domain of both insulin receptor gene alleles.";
RL   J. Biol. Chem. 266:5260-5267(1991).
RN   [84]
RP   VARIANT INS RESISTANCE ILE-1180.
RX   PubMed=1890161; DOI=10.1210/jcem-73-4-894;
RA   Cama A., de la Luz Sierra M., Ottini L., Kadowaki T., Gorden P.,
RA   Imperato-Mcginley J., Taylor S.I.;
RT   "A mutation in the tyrosine kinase domain of the insulin receptor
RT   associated with insulin resistance in an obese woman.";
RL   J. Clin. Endocrinol. Metab. 73:894-901(1991).
RN   [85]
RP   VARIANTS LEPRCH ALA-55 AND ARG-393.
RX   PubMed=1607067; DOI=10.2337/diab.41.4.408;
RA   Barbetti F., Gejman P.V., Taylor S.I., Raben N., Cama A., Bonora E.,
RA   Pizzo P., Moghetti P., Muggeo M., Roth J.;
RT   "Detection of mutations in insulin receptor gene by denaturing gradient gel
RT   electrophoresis.";
RL   Diabetes 41:408-415(1992).
RN   [86]
RP   VARIANT NIDDM GLN-1191.
RX   PubMed=1607076; DOI=10.2337/diab.41.4.521;
RA   Cocozza S., Porcellini A., Riccardi G., Monticelli A., Condorelli G.,
RA   Ferrara A., Pianese L., Miele C., Capaldo B., Beguinot F., Varrone S.;
RT   "NIDDM associated with mutation in tyrosine kinase domain of insulin
RT   receptor gene.";
RL   Diabetes 41:521-526(1992).
RN   [87]
RP   VARIANT IRAN TYPE A LEU-1205.
RX   PubMed=1563582; DOI=10.1007/bf00400927;
RA   Kim H., Kadowaki H., Sakura H., Odawara M., Momomura K., Takahashi Y.,
RA   Miyazaki Y., Ohtani T., Akanuma Y., Yazaki Y., Kasuga M., Taylor S.I.,
RA   Kadowaki T.;
RT   "Detection of mutations in the insulin receptor gene in patients with
RT   insulin resistance by analysis of single-stranded conformational
RT   polymorphisms.";
RL   Diabetologia 35:261-266(1992).
RN   [88]
RP   VARIANT LEPRCH ARG-58.
RX   PubMed=1730625; DOI=10.1016/s0021-9258(18)48459-1;
RA   van der Vorm E.R., van der Zon G.C.M., Moeller W., Krans H.M.J.,
RA   Lindhout D., Maassen J.A.;
RT   "An Arg for Gly substitution at position 31 in the insulin receptor, linked
RT   to insulin resistance, inhibits receptor processing and transport.";
RL   J. Biol. Chem. 267:66-71(1992).
RN   [89]
RP   VARIANT NIDDM GLN-1158.
RX   PubMed=1470163;
RA   Kasuga M., Kishimoto M., Hashiramoto M., Yonezawa K., Kazumi T., Hagino H.,
RA   Shii K.;
RT   "Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic loop of
RT   insulin receptor observed in insulin resistant diabetes.";
RL   Nihon Geka Gakkai Zasshi 93:968-971(1992).
RN   [90]
RP   VARIANT MET-1012.
RX   PubMed=8432414; DOI=10.2337/diab.42.3.429;
RA   Elbein S.C., Sorensen L.K., Schumacher M.C.;
RT   "Methionine for valine substitution in exon 17 of the insulin receptor gene
RT   in a pedigree with familial NIDDM.";
RL   Diabetes 42:429-434(1993).
RN   [91]
RP   VARIANT IRAN TYPE A ASP-1075.
RX   PubMed=8243830; DOI=10.2337/diab.42.12.1837;
RA   Haruta T., Takata Y., Iwanishi M., Maegawa H., Imamura T., Egawa K.,
RA   Itazu T., Kobayashi M.;
RT   "Ala1048-->Asp mutation in the kinase domain of insulin receptor causes
RT   defective kinase activity and insulin resistance.";
RL   Diabetes 42:1837-1844(1993).
RN   [92]
RP   VARIANT MET-1012.
RX   PubMed=8458533; DOI=10.1007/bf00400701;
RA   van der Vorm E.R., Kuipers A., Bonenkamp J.W., Kleijer W.J.,
RA   van Maldergem L., Herwig J., Maassen J.A.;
RT   "Patients with lipodystrophic diabetes mellitus of the Seip-Berardinelli
RT   type, express normal insulin receptors.";
RL   Diabetologia 36:172-174(1993).
RN   [93]
RP   VARIANT INS RESISTANCE LEU-1220.
RX   PubMed=8390949; DOI=10.1007/bf00402277;
RA   Iwanishi M., Haruta T., Takata Y., Ishibashi O., Sasaoka T., Egawa K.,
RA   Imamura T., Naitou K., Itazu T., Kobayashi M.;
RT   "A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the
RT   insulin receptor associated with type A syndrome of insulin resistance.";
RL   Diabetologia 36:414-422(1993).
RN   [94]
RP   VARIANT INS RESISTANCE LEU-220.
RX   PubMed=8242067; DOI=10.1093/hmg/2.9.1437;
RA   Carrera P., Cordera R., Ferrari M., Cremonesi L., Taramelli R.,
RA   Andraghetti G., Carducci C., Dozio N., Pozza G., Taylor S.I., Micossi P.,
RA   Barbetti F.;
RT   "Substitution of Leu for Pro-193 in the insulin receptor in a patient with
RT   a genetic form of severe insulin resistance.";
RL   Hum. Mol. Genet. 2:1437-1441(1993).
RN   [95]
RP   CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162.
RX   PubMed=8096518; DOI=10.1016/s0021-9258(18)53063-5;
RA   Cama A., de la Luz Sierra M., Quon M.J., Ottini L., Gorden P., Taylor S.I.;
RT   "Substitution of glutamic acid for alanine 1135 in the putative 'catalytic
RT   loop' of the tyrosine kinase domain of the human insulin receptor. A
RT   mutation that impairs proteolytic processing into subunits and inhibits
RT   receptor tyrosine kinase activity.";
RL   J. Biol. Chem. 268:8060-8069(1993).
RN   [96]
RP   VARIANT IRAN TYPE A VAL-409.
RX   PubMed=8388389; DOI=10.1016/s0021-9258(18)82120-2;
RA   Lebrun C., Baron V., Kaliman P., Gautier N., Dolais-Kitabgi J.,
RA   Taylor S.I., Accili D., van Obberghen E.;
RT   "Antibodies to the extracellular receptor domain restore the hormone-
RT   insensitive kinase and conformation of the mutant insulin receptor valine
RT   382.";
RL   J. Biol. Chem. 268:11272-11277(1993).
RN   [97]
RP   VARIANT LEPRCH MET-146.
RX   PubMed=8326490; DOI=10.1136/jmg.30.6.470;
RA   Al-Gazali L.I., Khalil M., Devadas K.;
RT   "A syndrome of insulin resistance resembling leprechaunism in five sibs of
RT   consanguineous parents.";
RL   J. Med. Genet. 30:470-475(1993).
RN   [98]
RP   VARIANT LEPRCH PRO-113.
RX   PubMed=8419945; DOI=10.1073/pnas.90.1.60;
RA   Longo N., Langley S.D., Griffin L.D., Elsas L.J.;
RT   "Activation of glucose transport by a natural mutation in the human insulin
RT   receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:60-64(1993).
RN   [99]
RP   VARIANT IRAN TYPE A GLN-1201.
RX   PubMed=8288049; DOI=10.2337/diab.43.2.247;
RA   Moller D.E., Cohen O., Yamaguchi Y., Assiz R., Grigorescu F., Eberle A.,
RA   Morrow L.A., Moses A.C., Flier J.S.;
RT   "Prevalence of mutations in the insulin receptor gene in subjects with
RT   features of the type A syndrome of insulin resistance.";
RL   Diabetes 43:247-255(1994).
RN   [100]
RP   VARIANT RMS SYNDROME LEU-350, VARIANTS IRAN TYPE A LEU-1205 AND GLN-1378,
RP   AND VARIANT MET-1012.
RX   PubMed=8314008; DOI=10.2337/diab.43.3.357;
RA   Krook A., Kumar S., Laing I., Boulton A.J., Wass J.A., O'Rahilly S.;
RT   "Molecular scanning of the insulin receptor gene in syndromes of insulin
RT   resistance.";
RL   Diabetes 43:357-368(1994).
RN   [101]
RP   CHARACTERIZATION OF VARIANT IRAN TYPE A GLN-1201.
RX   PubMed=8082780; DOI=10.1016/0014-5793(94)00876-0;
RA   Moritz W., Froesch E.R., Boeni-Schnetzler M.;
RT   "Functional properties of a heterozygous mutation (Arg1174-->Gln) in the
RT   tyrosine kinase domain of the insulin receptor from a type A insulin
RT   resistant patient.";
RL   FEBS Lett. 351:276-280(1994).
RN   [102]
RP   VARIANT LEPRCH SER-439.
RX   PubMed=8188715; DOI=10.1016/s0021-9258(17)36788-1;
RA   van der Vorm E.R., Kuipers A., Kielkopf-Renner S., Krans H.M.J., Moller W.,
RA   Maassen J.A.;
RT   "A mutation in the insulin receptor that impairs proreceptor processing but
RT   not insulin binding.";
RL   J. Biol. Chem. 269:14297-14302(1994).
RN   [103]
RP   CHARACTERIZATION OF VARIANTS IRAN TYPE A ASP-1206 AND LEU-1220.
RX   PubMed=7983039; DOI=10.1016/s0021-9258(18)47384-x;
RA   Imamura T., Takata Y., Sasaoka T., Takada Y., Morioka H., Haruta T.,
RA   Sawa T., Iwanishi M., Hu Y.G., Suzuki Y., Hamada J., Kobayashi M.;
RT   "Two naturally occurring mutations in the kinase domain of insulin receptor
RT   accelerate degradation of the insulin receptor and impair the kinase
RT   activity.";
RL   J. Biol. Chem. 269:31019-31027(1994).
RN   [104]
RP   VARIANT LEPRCH MET-146.
RX   PubMed=7815442; DOI=10.1136/jmg.31.9.715;
RA   Hone J., Accili D., al-Gazali L.I., Lestringant G., Orban T., Taylor S.I.;
RT   "Homozygosity for a new mutation (Ile119-->Met) in the insulin receptor
RT   gene in five sibs with familial insulin resistance.";
RL   J. Med. Genet. 31:715-716(1994).
RN   [105]
RP   VARIANT NIDDM ALA-858, AND VARIANT CYS-1361.
RX   PubMed=7657032; DOI=10.2337/diab.44.9.1081;
RA   Kan M., Kanai F., Iida M., Jinnouchi H., Todaka M., Imanaka T., Ito K.,
RA   Nishioka Y., Ohnishi T., Kamohara S., Hayashi H., Murakami T., Kagawa S.,
RA   Sano H., Hashimoto N., Yoshida S., Makino H., Ebina Y.;
RT   "Frequency of mutations of insulin receptor gene in Japanese patients with
RT   NIDDM.";
RL   Diabetes 44:1081-1086(1995).
RN   [106]
RP   VARIANT LEPRCH ASN-308 DEL.
RX   PubMed=7538143; DOI=10.1210/jcem.80.5.7538143;
RA   Longo N., Langley S.D., Griffin L.D., Elsas L.J.;
RT   "Two mutations in the insulin receptor gene of a patient with
RT   leprechaunism: application to prenatal diagnosis.";
RL   J. Clin. Endocrinol. Metab. 80:1496-1501(1995).
RN   [107]
RP   VARIANT PHE-1023.
RX   PubMed=8890729; DOI=10.1530/eje.0.1350357;
RA   Moritz W., Boeni-Schnetzler M., Stevens W., Froesch E.R., Levy J.R.;
RT   "In-frame exon 2 deletion in insulin receptor RNA in a family with extreme
RT   insulin resistance in association with defective insulin binding: a case
RT   report.";
RL   Eur. J. Endocrinol. 135:357-363(1996).
RN   [108]
RP   VARIANT LEPRCH ASN-308 DEL.
RX   PubMed=8636294; DOI=10.1210/jcem.81.2.8636294;
RA   Desbois-Mouthon C., Sert-Langeron C., Magre J., Oreal E., Blivet M.J.,
RA   Flori E., Besmond C., Capeau J., Caron M.;
RT   "Deletion of Asn281 in the alpha-subunit of the human insulin receptor
RT   causes constitutive activation of the receptor and insulin
RT   desensitization.";
RL   J. Clin. Endocrinol. Metab. 81:719-727(1996).
RN   [109]
RP   VARIANT MET-1012.
RX   PubMed=9199575; DOI=10.1086/515464;
RA   Hansen L., Hansen T., Clausen J.O., Echwald S.M., Urhammer S.A.,
RA   Rasmussen S.K., Pedersen O.;
RT   "The Val985Met insulin-receptor variant in the Danish Caucasian population:
RT   lack of associations with non-insulin-dependent diabetes mellitus or
RT   insulin resistance.";
RL   Am. J. Hum. Genet. 60:1532-1535(1997).
RN   [110]
RP   VARIANTS IRAN TYPE A GLY-86 AND PRO-89.
RX   PubMed=9175790; DOI=10.1006/bbrc.1997.6695;
RA   Rouard M., Macari F., Bouix O., Lautier C., Brun J.F., Lefebvre P.,
RA   Renard E., Bringer J., Jaffiol C., Grigorescu F.;
RT   "Identification of two novel insulin receptor mutations, Asp59Gly and
RT   Leu62Pro, in type A syndrome of extreme insulin resistance.";
RL   Biochem. Biophys. Res. Commun. 234:764-768(1997).
RN   [111]
RP   CHARACTERIZATION OF VARIANT LEPRCH MET-937.
RX   PubMed=9299395; DOI=10.1006/bbrc.1997.7181;
RA   Kadowaki H., Takahashi Y., Ando A., Momomura K., Kaburagi Y., Quin J.D.,
RA   MacCuish A.C., Koda N., Fukushima Y., Taylor S.I., Akanuma Y., Yazaki Y.,
RA   Kadowaki T.;
RT   "Four mutant alleles of the insulin receptor gene associated with genetic
RT   syndromes of extreme insulin resistance.";
RL   Biochem. Biophys. Res. Commun. 237:516-520(1997).
RN   [112]
RP   VARIANTS LEPRCH TRP-1119 AND LYS-1206.
RX   PubMed=9249867;
RX   DOI=10.1002/(sici)1097-0223(199707)17:7<657::aid-pd132>3.0.co;2-8;
RA   Desbois-Mouthon C., Girodon E., Ghanem N., Caron M., Pennerath A.,
RA   Conteville P., Magre J., Besmond C., Goossens M., Capeau J., Amselem S.;
RT   "Molecular analysis of the insulin receptor gene for prenatal diagnosis of
RT   leprechaunism in two families.";
RL   Prenat. Diagn. 17:657-663(1997).
RN   [113]
RP   VARIANTS LEPRCH TYR-301 AND TRP-1201.
RX   PubMed=9703342; DOI=10.2337/diab.47.8.1362;
RA   Whitehead J.P., Soos M.A., Jackson R., Tasic V., Kocova M., O'Rahilly S.;
RT   "Multiple molecular mechanisms of insulin receptor dysfunction in a patient
RT   with Donohue syndrome.";
RL   Diabetes 47:1362-1364(1998).
RN   [114]
RP   VARIANTS RMS THR-1143 AND TRP-1158.
RX   PubMed=10443650; DOI=10.1210/jcem.84.8.5902;
RA   Longo N., Wang Y., Pasquali M.;
RT   "Progressive decline in insulin levels in Rabson-Mendenhall syndrome.";
RL   J. Clin. Endocrinol. Metab. 84:2623-2629(1999).
RN   [115]
RP   VARIANTS IRAN TYPE A LEU-167 AND VAL-1055.
RX   PubMed=10733238; DOI=10.1034/j.1399-0004.2000.570110.x;
RA   Rique S., Nogues C., Ibanez L., Marcos M.V., Ferragut J., Carrascosa A.,
RA   Potau N.;
RT   "Identification of three novel mutations in the insulin receptor gene in
RT   type A insulin resistant patients.";
RL   Clin. Genet. 57:67-69(2000).
RN   [116]
RP   VARIANT IRAN TYPE A TYR-280.
RX   PubMed=11260230; DOI=10.1034/j.1399-0004.2001.590309.x;
RA   Osawa H., Nishimiya T., Ochi M., Niiya T., Onuma H., Kitamuro F., Kaino Y.,
RA   Kida K., Makino H.;
RT   "Identification of novel C253Y missense and Y864X nonsense mutations in the
RT   insulin receptor gene in type A insulin-resistant patients.";
RL   Clin. Genet. 59:194-197(2001).
RN   [117]
RP   VARIANT IRAN TYPE A CYS-279.
RX   PubMed=12107746; DOI=10.1007/s00125-002-0798-5;
RA   Hamer I., Foti M., Emkey R., Cordier-Bussat M., Philippe J., De Meyts P.,
RA   Maeder C., Kahn C.R., Carpentier J.-L.;
RT   "An arginine to cysteine(252) mutation in insulin receptors from a patient
RT   with severe insulin resistance inhibits receptor internalisation but
RT   preserves signalling events.";
RL   Diabetologia 45:657-667(2002).
RN   [118]
RP   CHARACTERIZATION OF VARIANTS LEPRCH PRO-113; VAL-119; ASN-308 DEL; THR-925
RP   AND TRP-926, AND VARIANTS RMS THR-997; THR-1143; TRP-1158 AND TRP-1201.
RX   PubMed=12023989; DOI=10.1093/hmg/11.12.1465;
RA   Longo N., Wang Y., Smith S.A., Langley S.D., DiMeglio L.A.,
RA   Giannella-Neto D.;
RT   "Genotype-phenotype correlation in inherited severe insulin resistance.";
RL   Hum. Mol. Genet. 11:1465-1475(2002).
RN   [119]
RP   VARIANT LEPRCH VAL-362 DEL.
RX   PubMed=12538626; DOI=10.1210/en.2002-220815;
RA   George S., Johansen A., Soos M.A., Mortensen H., Gammeltoft S., Saudek V.,
RA   Siddle K., Hansen L., O'Rahilly S.;
RT   "Deletion of V335 from the L2 domain of the insulin receptor results in a
RT   conformationally abnormal receptor that is unable to bind insulin and
RT   causes Donohue's syndrome in a human subject.";
RL   Endocrinology 144:631-637(2003).
RN   [120]
RP   VARIANT IRAN TYPE A HIS-279, VARIANTS LEPRCH GLN-120; LEU-350; ASP-458 AND
RP   TRP-1119, CHARACTERIZATION OF VARIANT IRAN TYPE A HIS-279, AND
RP   CHARACTERIZATION OF VARIANTS LEPRCH GLN-120 AND ASP-458.
RX   PubMed=12970295; DOI=10.1210/jc.2003-030034;
RA   Maassen J.A., Tobias E.S., Kayserilli H., Tukel T., Yuksel-Apak M.,
RA   D'Haens E., Kleijer W.J., Fery F., van der Zon G.C.M.;
RT   "Identification and functional assessment of novel and known insulin
RT   receptor mutations in five patients with syndromes of severe insulin
RT   resistance.";
RL   J. Clin. Endocrinol. Metab. 88:4251-4257(2003).
RN   [121]
RP   VARIANT HHF5 GLN-1201.
RX   PubMed=15161766; DOI=10.2337/diabetes.53.6.1592;
RA   Hoejlund K., Hansen T., Lajer M., Henriksen J.E., Levin K., Lindholm J.,
RA   Pedersen O., Bech-Nielsen H.;
RT   "A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia
RT   linked to a mutation in the human insulin receptor gene.";
RL   Diabetes 53:1592-1598(2004).
RN   [122]
RP   VARIANTS RMS ARG-236 AND SER-386, AND CHARACTERIZATION OF VARIANTS RMS
RP   ARG-236 AND SER-386.
RX   PubMed=17201797; DOI=10.1111/j.1365-2265.2006.02678.x;
RA   Tuthill A., Semple R.K., Day R., Soos M.A., Sweeney E., Seymour P.J.,
RA   Didi M., O'Rahilly S.;
RT   "Functional characterization of a novel insulin receptor mutation
RT   contributing to Rabson-Mendenhall syndrome.";
RL   Clin. Endocrinol. (Oxf.) 66:21-26(2007).
RN   [123]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-228; ARG-695; SER-811; MET-1012;
RP   VAL-1065 AND ALA-1282.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [124]
RP   VARIANTS LEPRCH CYS-818 AND 890-ARG--SER-1382 DEL.
RX   PubMed=22768670; DOI=10.1515/jpem-2011-0448;
RA   Nobile S., Semple R.K., Carnielli V.P.;
RT   "A novel mutation of the insulin receptor gene in a preterm infant with
RT   Donohue syndrome and heart failure.";
RL   J. Pediatr. Endocrinol. Metab. 25:363-366(2012).
RN   [125]
RP   VARIANTS LEPRCH THR-56 AND TYR-286, AND CHARACTERIZATION OF VARIANTS LEPRCH
RP   THR-56 AND TYR-286.
RX   PubMed=24498630; DOI=10.1002/mgg3.43;
RA   Falik Zaccai T.C., Kalfon L., Klar A., Elisha M.B., Hurvitz H.,
RA   Weingarten G., Chechik E., Fleisher Sheffer V., Haj Yahya R., Meidan G.,
RA   Gross-Kieselstein E., Bauman D., Hershkovitz S., Yaron Y., Orr-Urtreger A.,
RA   Wertheimer E.;
RT   "Two novel mutations identified in familial cases with Donohue syndrome.";
RL   Mol. Genet. Genomic Med. 2:64-72(2014).
RN   [126]
RP   VARIANTS RMS CYS-256; LEU-635; ILE-835; VAL-842; LEU-874; SER-878 AND
RP   999-TYR--SER-1382 DEL, VARIANTS IRAN TYPE A ASP-489 AND MET-1054, VARIANTS
RP   LEPRCH PHE-657; ARG-659 AND CYS-818, CHARACTERIZATION OF VARIANTS LEPRCH
RP   PHE-657; ARG-659; CYS-818; THR-925; TRP-926 AND MET-937, AND
RP   CHARACTERIZATION OF VARIANTS RMS LEU-635; ILE-835; VAL-842; LEU-874 AND
RP   SER-878.
RX   PubMed=28765322; DOI=10.2337/db17-0301;
RA   Hosoe J., Kadowaki H., Miya F., Aizu K., Kawamura T., Miyata I.,
RA   Satomura K., Ito T., Hara K., Tanaka M., Ishiura H., Tsuji S., Suzuki K.,
RA   Takakura M., Boroevich K.A., Tsunoda T., Yamauchi T., Shojima N.,
RA   Kadowaki T.;
RT   "Structural Basis and Genotype-Phenotype Correlations of INSR Mutations
RT   Causing Severe Insulin Resistance.";
RL   Diabetes 66:2713-2723(2017).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic
CC       actions of insulin. Binding of insulin leads to phosphorylation of
CC       several intracellular substrates, including, insulin receptor
CC       substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling
CC       intermediates. Each of these phosphorylated proteins serve as docking
CC       proteins for other signaling proteins that contain Src-homology-2
CC       domains (SH2 domain) that specifically recognize different
CC       phosphotyrosine residues, including the p85 regulatory subunit of PI3K
CC       and SHP2. Phosphorylation of IRSs proteins lead to the activation of
CC       two main signaling pathways: the PI3K-AKT/PKB pathway, which is
CC       responsible for most of the metabolic actions of insulin, and the Ras-
CC       MAPK pathway, which regulates expression of some genes and cooperates
CC       with the PI3K pathway to control cell growth and differentiation.
CC       Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to
CC       the activation of PI3K and the generation of phosphatidylinositol-(3,
CC       4, 5)-triphosphate (PIP3), a lipid second messenger, which activates
CC       several PIP3-dependent serine/threonine kinases, such as PDPK1 and
CC       subsequently AKT/PKB. The net effect of this pathway is to produce a
CC       translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic
CC       vesicles to the cell membrane to facilitate glucose transport.
CC       Moreover, upon insulin stimulation, activated AKT/PKB is responsible
CC       for: anti-apoptotic effect of insulin by inducing phosphorylation of
CC       BAD; regulates the expression of gluconeogenic and lipogenic enzymes by
CC       controlling the activity of the winged helix or forkhead (FOX) class of
CC       transcription factors. Another pathway regulated by PI3K-AKT/PKB
CC       activation is mTORC1 signaling pathway which regulates cell growth and
CC       metabolism and integrates signals from insulin. AKT mediates insulin-
CC       stimulated protein synthesis by phosphorylating TSC2 thereby activating
CC       mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in
CC       mediating cell growth, survival and cellular differentiation of
CC       insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers
CC       the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to
CC       binding insulin, the insulin receptor can bind insulin-like growth
CC       factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII
CC       binding. When present in a hybrid receptor with IGF1R, binds IGF1.
CC       PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR
CC       isoform Long are activated with a high affinity by IGF1, with low
CC       affinity by IGF2 and not significantly activated by insulin, and that
CC       hybrid receptors composed of IGF1R and INSR isoform Short are activated
CC       by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that
CC       hybrid receptors composed of IGF1R and INSR isoform Long and hybrid
CC       receptors composed of IGF1R and INSR isoform Short have similar binding
CC       characteristics, both bind IGF1 and have a low affinity for insulin. In
CC       adipocytes, inhibits lipolysis (By similarity).
CC       {ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:12138094,
CC       ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16831875,
CC       ECO:0000269|PubMed:8257688, ECO:0000269|PubMed:8276809,
CC       ECO:0000269|PubMed:8452530, ECO:0000269|PubMed:9428692}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11598120,
CC         ECO:0000269|PubMed:12707268, ECO:0000269|PubMed:18278056,
CC         ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018,
CC         ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:9312016};
CC   -!- ACTIVITY REGULATION: Activated in response to insulin.
CC       Autophosphorylation activates the kinase activity. PTPN1, PTPRE and
CC       PTPRF dephosphorylate important tyrosine residues, thereby reducing
CC       INSR activity. Inhibited by ENPP1. GRB10 and GRB14 inhibit the
CC       catalytic activity of the INSR, they block access of substrates to the
CC       activated receptor. SOCS1 and SOCS3 act as negative regulators of INSR
CC       activity, they bind to the activated INRS and interfere with the
CC       phosphorylation of INSR substrates. {ECO:0000269|PubMed:10615944,
CC       ECO:0000269|PubMed:11598120, ECO:0000269|PubMed:11726652,
CC       ECO:0000269|PubMed:12493740, ECO:0000269|PubMed:2211730}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains carry the insulin-binding regions, while the
CC       beta chains carry the kinase domain. Forms a hybrid receptor with
CC       IGF1R, the hybrid is a tetramer consisting of 1 alpha chain and 1 beta
CC       chain of INSR and 1 alpha chain and 1 beta chain of IGF1R. Interacts
CC       with SORBS1 but dissociates from it following insulin stimulation.
CC       Binds SH2B2. Activated form of INSR interacts (via Tyr-999) with the
CC       PTB/PID domains of IRS1 and SHC1. The sequences surrounding the
CC       phosphorylated NPXY motif contribute differentially to either IRS1 or
CC       SHC1 recognition. Interacts (via tyrosines in the C-terminus) with IRS2
CC       (via PTB domain and 591-786 AA); the 591-786 would be the primary
CC       anchor of IRS2 to INSR while the PTB domain would have a stabilizing
CC       action on the interaction with INSR. Interacts with the SH2 domains of
CC       the 85 kDa regulatory subunit of PI3K (PIK3R1) in vitro, when
CC       autophosphorylated on tyrosine residues. Interacts with SOCS7.
CC       Interacts (via the phosphorylated Tyr-999), with SOCS3. Interacts (via
CC       the phosphorylated Tyr-1185, Tyr-1189, Tyr-1190) with SOCS1. Interacts
CC       with CAV2 (tyrosine-phosphorylated form); the interaction is increased
CC       with 'Tyr-27'phosphorylation of CAV2 (By similarity). Interacts with
CC       ARRB2 (By similarity). Interacts with GRB10; this interaction blocks
CC       the association between IRS1/IRS2 and INSR, significantly reduces
CC       insulin-stimulated tyrosine phosphorylation of IRS1 and IRS2 and thus
CC       decreases insulin signaling. Interacts with GRB7. Interacts with PDPK1.
CC       Interacts (via Tyr-1190) with GRB14 (via BPS domain); this interaction
CC       protects the tyrosines in the activation loop from dephosphorylation,
CC       but promotes dephosphorylation of Tyr-999, this results in decreased
CC       interaction with, and phosphorylation of, IRS1. Interacts (via subunit
CC       alpha) with ENPP1 (via 485-599 AA); this interaction blocks
CC       autophosphorylation. Interacts with PTPRE; this interaction is
CC       dependent of Tyr-1185, Tyr-1189 and Tyr-1190 of the INSR. Interacts
CC       with STAT5B (via SH2 domain). Interacts with PTPRF. Interacts with
CC       ATIC; ATIC together with PRKAA2/AMPK2 and HACD3/PTPLAD1 is proposed to
CC       be part of a signaling netwok regulating INSR autophosphorylation and
CC       endocytosis (By similarity). Interacts with the cone snail venom
CC       insulin Con-Ins G1 (PubMed:27617429). Interacts with the insulin
CC       receptor SORL1; this interaction strongly increases its surface
CC       exposure, hence strengthens insulin signal reception (PubMed:27322061).
CC       Interacts (tyrosine phosphorylated) with CCDC88A/GIV (via SH2-like
CC       region); binding requires autophosphorylation of the INSR C-terminal
CC       region (PubMed:25187647). Interacts with GNAI3; the interaction is
CC       probably mediated by CCDC88A/GIV (PubMed:25187647). Interacts with
CC       LMBRD1 (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:P15127,
CC       ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:10615944,
CC       ECO:0000269|PubMed:10803466, ECO:0000269|PubMed:11124964,
CC       ECO:0000269|PubMed:11374898, ECO:0000269|PubMed:11726652,
CC       ECO:0000269|PubMed:12493740, ECO:0000269|PubMed:14690593,
CC       ECO:0000269|PubMed:16127460, ECO:0000269|PubMed:16246733,
CC       ECO:0000269|PubMed:16271887, ECO:0000269|PubMed:16314505,
CC       ECO:0000269|PubMed:16957736, ECO:0000269|PubMed:18278056,
CC       ECO:0000269|PubMed:18767165, ECO:0000269|PubMed:19056263,
CC       ECO:0000269|PubMed:19071018, ECO:0000269|PubMed:19394223,
CC       ECO:0000269|PubMed:2211730, ECO:0000269|PubMed:23302862,
CC       ECO:0000269|PubMed:25187647, ECO:0000269|PubMed:27322061,
CC       ECO:0000269|PubMed:27617429, ECO:0000269|PubMed:7537849,
CC       ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:8276809,
CC       ECO:0000269|PubMed:8995282, ECO:0000269|PubMed:8999839,
CC       ECO:0000269|PubMed:9312016, ECO:0000269|PubMed:9428692}.
CC   -!- INTERACTION:
CC       P06213; Q99490: AGAP2; NbExp=2; IntAct=EBI-475899, EBI-2361824;
CC       P06213; Q8NEJ0: DUSP18; NbExp=2; IntAct=EBI-475899, EBI-10698945;
CC       P06213; Q13322: GRB10; NbExp=3; IntAct=EBI-475899, EBI-80275;
CC       P06213; P05019: IGF1; NbExp=4; IntAct=EBI-475899, EBI-7902275;
CC       P06213; P08069: IGF1R; NbExp=4; IntAct=EBI-475899, EBI-475981;
CC       P06213; P14616: INSRR; NbExp=4; IntAct=EBI-475899, EBI-6424336;
CC       P06213; P35568: IRS1; NbExp=3; IntAct=EBI-475899, EBI-517592;
CC       P06213; Q15323: KRT31; NbExp=3; IntAct=EBI-475899, EBI-948001;
CC       P06213; P27986: PIK3R1; NbExp=5; IntAct=EBI-475899, EBI-79464;
CC       P06213; P19174: PLCG1; NbExp=9; IntAct=EBI-475899, EBI-79387;
CC       P06213; P18031: PTPN1; NbExp=33; IntAct=EBI-475899, EBI-968788;
CC       P06213; Q06124: PTPN11; NbExp=3; IntAct=EBI-475899, EBI-297779;
CC       P06213; Q15256: PTPRR; NbExp=2; IntAct=EBI-475899, EBI-2265659;
CC       P06213; Q9NRF2: SH2B1; NbExp=6; IntAct=EBI-475899, EBI-310491;
CC       P06213; P29353: SHC1; NbExp=2; IntAct=EBI-475899, EBI-78835;
CC       P06213; P01317: INS; Xeno; NbExp=5; IntAct=EBI-475899, EBI-3989070;
CC       P06213; P35570: Irs1; Xeno; NbExp=5; IntAct=EBI-475899, EBI-520230;
CC       P06213-1; P32121: ARRB2; NbExp=2; IntAct=EBI-15558981, EBI-714559;
CC       P06213-1; P06213-1: INSR; NbExp=4; IntAct=EBI-15558981, EBI-15558981;
CC       P06213-1; P18031: PTPN1; NbExp=2; IntAct=EBI-15558981, EBI-968788;
CC       P06213-1; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-15558981, EBI-21501656;
CC       P06213-1; P81122: Irs2; Xeno; NbExp=8; IntAct=EBI-15558981, EBI-1369862;
CC       P06213-1; Q1XH17: Trim72; Xeno; NbExp=2; IntAct=EBI-15558981, EBI-16034016;
CC       P06213-2; P01308: INS; NbExp=6; IntAct=EBI-9984921, EBI-7090529;
CC       P06213-2; Q13257: MAD2L1; NbExp=3; IntAct=EBI-9984921, EBI-78203;
CC       P06213-2; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-9984921, EBI-21501656;
CC       P06213-2; P01317: INS; Xeno; NbExp=2; IntAct=EBI-9984921, EBI-3989070;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P15208};
CC       Single-pass type I membrane protein {ECO:0000305}. Late endosome
CC       {ECO:0000250|UniProtKB:P15208}. Lysosome
CC       {ECO:0000250|UniProtKB:P15208}. Note=Binding of insulin to INSR induces
CC       internalization and lysosomal degradation of the receptor, a means for
CC       down-regulating this signaling pathway after stimulation. In the
CC       presence of SORL1, internalized INSR molecules are redirected back to
CC       the cell surface, thereby preventing their lysosomal catabolism and
CC       strengthening insulin signal reception. {ECO:0000250|UniProtKB:P15208}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long; Synonyms=HIR-B;
CC         IsoId=P06213-1; Sequence=Displayed;
CC       Name=Short; Synonyms=HIR-A;
CC         IsoId=P06213-2; Sequence=VSP_002898;
CC   -!- TISSUE SPECIFICITY: Isoform Long and isoform Short are predominantly
CC       expressed in tissue targets of insulin metabolic effects: liver,
CC       adipose tissue and skeletal muscle but are also expressed in the
CC       peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta
CC       vascular endothelium, fibroblasts, monocytes, granulocytes,
CC       erythrocytes and skin. Isoform Short is preferentially expressed in
CC       fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found
CC       as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose
CC       tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at
CC       protein level). Overexpressed in several tumors, including breast,
CC       colon, lung, ovary, and thyroid carcinomas.
CC       {ECO:0000269|PubMed:10207053, ECO:0000269|PubMed:2369896,
CC       ECO:0000269|PubMed:9202395, ECO:0000269|PubMed:9355755}.
CC   -!- DOMAIN: The tetrameric insulin receptor binds insulin via non-identical
CC       regions from two alpha chains, primarily via the C-terminal region of
CC       the first INSR alpha chain. Residues from the leucine-rich N-terminus
CC       of the other INSR alpha chain also contribute to this insulin binding
CC       site. A secondary insulin-binding site is formed by residues at the
CC       junction of fibronectin type-III domain 1 and 2.
CC       {ECO:0000269|PubMed:16957736, ECO:0000269|PubMed:19459609,
CC       ECO:0000269|PubMed:23302862}.
CC   -!- PTM: After being transported from the endoplasmic reticulum to the
CC       Golgi apparatus, the single glycosylated precursor is further
CC       glycosylated and then cleaved, followed by its transport to the plasma
CC       membrane. {ECO:0000269|PubMed:1472036, ECO:0000269|PubMed:16894147,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973,
CC       ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to insulin.
CC       Phosphorylation of Tyr-999 is required for binding to IRS1, SHC1 and
CC       STAT5B. Dephosphorylated by PTPRE at Tyr-999, Tyr-1185, Tyr-1189 and
CC       Tyr-1190. Dephosphorylated by PTPRF and PTPN1. Dephosphorylated by
CC       PTPN2; down-regulates insulin-induced signaling.
CC       {ECO:0000269|PubMed:10734133, ECO:0000269|PubMed:12612081,
CC       ECO:0000269|PubMed:14690593, ECO:0000269|PubMed:16246733,
CC       ECO:0000269|PubMed:16271887, ECO:0000269|PubMed:18278056,
CC       ECO:0000269|PubMed:18767165, ECO:0000269|PubMed:3166375,
CC       ECO:0000269|PubMed:9312016}.
CC   -!- DISEASE: Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe insulin
CC       resistance syndrome characterized by insulin-resistant diabetes
CC       mellitus with pineal hyperplasia and somatic abnormalities. Typical
CC       features include coarse, senile-appearing facies, dental and skin
CC       abnormalities, abdominal distension, and phallic enlargement.
CC       Inheritance is autosomal recessive. {ECO:0000269|PubMed:10443650,
CC       ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:17201797,
CC       ECO:0000269|PubMed:2121734, ECO:0000269|PubMed:2365819,
CC       ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:8314008}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Leprechaunism (LEPRCH) [MIM:246200]: Represents the most
CC       severe form of insulin resistance syndrome, characterized by
CC       intrauterine and postnatal growth retardation and death in early
CC       infancy. Inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:12538626,
CC       ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1607067,
CC       ECO:0000269|PubMed:1730625, ECO:0000269|PubMed:22768670,
CC       ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:24498630,
CC       ECO:0000269|PubMed:2479553, ECO:0000269|PubMed:2834824,
CC       ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:7538143,
CC       ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8188715,
CC       ECO:0000269|PubMed:8326490, ECO:0000269|PubMed:8419945,
CC       ECO:0000269|PubMed:8636294, ECO:0000269|PubMed:9249867,
CC       ECO:0000269|PubMed:9299395, ECO:0000269|PubMed:9703342}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]:
CC       A multifactorial disorder of glucose homeostasis caused by a lack of
CC       sensitivity to the body's own insulin. Affected individuals usually
CC       have an obese body habitus and manifestations of a metabolic syndrome
CC       characterized by diabetes, insulin resistance, hypertension and
CC       hypertriglyceridemia. The disease results in long-term complications
CC       that affect the eyes, kidneys, nerves, and blood vessels.
CC       {ECO:0000269|PubMed:1470163, ECO:0000269|PubMed:1607076,
CC       ECO:0000269|PubMed:7657032}. Note=The gene represented in this entry
CC       may be involved in disease pathogenesis.
CC   -!- DISEASE: Familial hyperinsulinemic hypoglycemia 5 (HHF5) [MIM:609968]:
CC       Familial hyperinsulinemic hypoglycemia [MIM:256450], also referred to
CC       as congenital hyperinsulinism, nesidioblastosis, or persistent
CC       hyperinsulinemic hypoglycemia of infancy (PPHI), is the most common
CC       cause of persistent hypoglycemia in infancy and is due to defective
CC       negative feedback regulation of insulin secretion by low glucose
CC       levels. {ECO:0000269|PubMed:15161766}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Insulin-resistant diabetes mellitus with acanthosis nigricans
CC       type A (IRAN type A) [MIM:610549]: Characterized by the association of
CC       severe insulin resistance (manifested by marked hyperinsulinemia and a
CC       failure to respond to exogenous insulin) with the skin lesion
CC       acanthosis nigricans and ovarian hyperandrogenism in adolescent female
CC       subjects. Women frequently present with hirsutism, acne, amenorrhea or
CC       oligomenorrhea, and virilization. This syndrome is different from the
CC       type B that has been demonstrated to be secondary to the presence of
CC       circulating autoantibodies against the insulin receptor.
CC       {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230,
CC       ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295,
CC       ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473,
CC       ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397,
CC       ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998,
CC       ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:3283938,
CC       ECO:0000269|PubMed:8243830, ECO:0000269|PubMed:8288049,
CC       ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8388389,
CC       ECO:0000269|PubMed:9175790}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Insulin_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M10051; AAA59174.1; -; mRNA.
DR   EMBL; X02160; CAA26096.1; -; mRNA.
DR   EMBL; M32972; AAA59452.1; -; Genomic_DNA.
DR   EMBL; M23100; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32823; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32824; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32825; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32826; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32827; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32828; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32829; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32830; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32831; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32832; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32833; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32834; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32835; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32836; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32837; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32838; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32839; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32840; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32841; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32842; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; AC010311; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010526; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010606; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC125387; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC117172; AAI17173.1; -; mRNA.
DR   EMBL; J03466; AAA59175.1; -; Genomic_DNA.
DR   EMBL; J05043; AAA59190.1; -; Genomic_DNA.
DR   EMBL; M76592; AAC37604.1; -; Genomic_DNA.
DR   EMBL; AB208861; BAD92098.1; -; mRNA.
DR   EMBL; M24555; AAA59178.1; -; mRNA.
DR   EMBL; M29929; AAA59176.1; -; Genomic_DNA.
DR   EMBL; M29930; AAA59177.1; -; Genomic_DNA.
DR   EMBL; M27197; AAA86791.1; -; Genomic_DNA.
DR   EMBL; M27195; AAA86791.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS12176.1; -. [P06213-1]
DR   CCDS; CCDS42487.1; -. [P06213-2]
DR   PIR; A37348; INHUR.
DR   RefSeq; NP_000199.2; NM_000208.3. [P06213-1]
DR   RefSeq; NP_001073285.1; NM_001079817.2. [P06213-2]
DR   PDB; 1GAG; X-ray; 2.70 A; A=1005-1310.
DR   PDB; 1I44; X-ray; 2.40 A; A=1005-1310.
DR   PDB; 1IR3; X-ray; 1.90 A; A=1005-1310.
DR   PDB; 1IRK; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 1P14; X-ray; 1.90 A; A=1005-1310.
DR   PDB; 1RQQ; X-ray; 2.60 A; A/B=1005-1310.
DR   PDB; 2AUH; X-ray; 3.20 A; A=1005-1310.
DR   PDB; 2B4S; X-ray; 2.30 A; B/D=1005-1310.
DR   PDB; 2HR7; X-ray; 2.32 A; A/B=28-512.
DR   PDB; 2MFR; NMR; -; A=940-988.
DR   PDB; 2Z8C; X-ray; 3.25 A; A=1008-1310.
DR   PDB; 3BU3; X-ray; 1.65 A; A=1005-1310.
DR   PDB; 3BU5; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 3BU6; X-ray; 1.95 A; A=1005-1310.
DR   PDB; 3EKK; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 3EKN; X-ray; 2.20 A; A=1005-1310.
DR   PDB; 3ETA; X-ray; 2.60 A; A/B=1017-1322.
DR   PDB; 3W11; X-ray; 3.90 A; E=28-337, F=731-744.
DR   PDB; 3W12; X-ray; 4.30 A; E=28-337, F=731-744.
DR   PDB; 3W13; X-ray; 4.30 A; E=28-337, F=724-744.
DR   PDB; 4IBM; X-ray; 1.80 A; A/B=1005-1310.
DR   PDB; 4OGA; X-ray; 3.50 A; E=28-337, F=731-744.
DR   PDB; 4XLV; X-ray; 2.30 A; A=983-1310.
DR   PDB; 4XSS; X-ray; 3.00 A; E=28-337.
DR   PDB; 4XST; X-ray; 3.00 A; E=28-337.
DR   PDB; 4ZXB; X-ray; 3.30 A; E=28-956.
DR   PDB; 5E1S; X-ray; 2.26 A; A=1005-1310.
DR   PDB; 5HHW; X-ray; 1.79 A; A=1005-1310.
DR   PDB; 5J3H; X-ray; 3.27 A; E=28-337.
DR   PDB; 5KQV; X-ray; 4.40 A; E/F=28-746.
DR   PDB; 5U1M; X-ray; 1.80 A; B=991-999.
DR   PDB; 6HN4; EM; 4.20 A; E/F=28-955.
DR   PDB; 6HN5; EM; 3.20 A; E/F=28-955.
DR   PDB; 6PXV; EM; 3.20 A; A/C=28-1382.
DR   PDB; 6PXW; EM; 3.10 A; A/B=28-1382.
DR   PDB; 6SOF; EM; 4.30 A; A/C=28-746, B/D=795-956.
DR   PDB; 6VEP; X-ray; 2.90 A; E/K/Q/W=28-337, F/L/R/X=731-746.
DR   PDB; 6VEQ; X-ray; 3.25 A; E/K=28-337, F/L=731-746.
DR   PDB; 7BW7; EM; 4.10 A; A/C=28-1382.
DR   PDB; 7BW8; EM; 3.80 A; A/C=28-1382.
DR   PDB; 7BWA; EM; 4.90 A; A/C=28-1382.
DR   PDB; 7KD6; X-ray; 2.60 A; E/K/Q/W=28-337.
DR   PDB; 7MQO; EM; 3.40 A; E/F=28-956.
DR   PDB; 7MQR; EM; 4.10 A; E/F=28-955.
DR   PDB; 7MQS; EM; 4.40 A; E/F=28-955.
DR   PDB; 7PG0; EM; 7.60 A; A/B=1-1382.
DR   PDB; 7PG2; EM; 6.70 A; A/B=1-1382.
DR   PDB; 7PG3; EM; 7.30 A; A/B=1-1382.
DR   PDB; 7PG4; EM; 9.10 A; A/B=1-1382.
DR   PDB; 7QID; EM; 5.00 A; A/C=28-746, B/D=763-956.
DR   PDBsum; 1GAG; -.
DR   PDBsum; 1I44; -.
DR   PDBsum; 1IR3; -.
DR   PDBsum; 1IRK; -.
DR   PDBsum; 1P14; -.
DR   PDBsum; 1RQQ; -.
DR   PDBsum; 2AUH; -.
DR   PDBsum; 2B4S; -.
DR   PDBsum; 2HR7; -.
DR   PDBsum; 2MFR; -.
DR   PDBsum; 2Z8C; -.
DR   PDBsum; 3BU3; -.
DR   PDBsum; 3BU5; -.
DR   PDBsum; 3BU6; -.
DR   PDBsum; 3EKK; -.
DR   PDBsum; 3EKN; -.
DR   PDBsum; 3ETA; -.
DR   PDBsum; 3W11; -.
DR   PDBsum; 3W12; -.
DR   PDBsum; 3W13; -.
DR   PDBsum; 4IBM; -.
DR   PDBsum; 4OGA; -.
DR   PDBsum; 4XLV; -.
DR   PDBsum; 4XSS; -.
DR   PDBsum; 4XST; -.
DR   PDBsum; 4ZXB; -.
DR   PDBsum; 5E1S; -.
DR   PDBsum; 5HHW; -.
DR   PDBsum; 5J3H; -.
DR   PDBsum; 5KQV; -.
DR   PDBsum; 5U1M; -.
DR   PDBsum; 6HN4; -.
DR   PDBsum; 6HN5; -.
DR   PDBsum; 6PXV; -.
DR   PDBsum; 6PXW; -.
DR   PDBsum; 6SOF; -.
DR   PDBsum; 6VEP; -.
DR   PDBsum; 6VEQ; -.
DR   PDBsum; 7BW7; -.
DR   PDBsum; 7BW8; -.
DR   PDBsum; 7BWA; -.
DR   PDBsum; 7KD6; -.
DR   PDBsum; 7MQO; -.
DR   PDBsum; 7MQR; -.
DR   PDBsum; 7MQS; -.
DR   PDBsum; 7PG0; -.
DR   PDBsum; 7PG2; -.
DR   PDBsum; 7PG3; -.
DR   PDBsum; 7PG4; -.
DR   PDBsum; 7QID; -.
DR   AlphaFoldDB; P06213; -.
DR   BMRB; P06213; -.
DR   SASBDB; P06213; -.
DR   SMR; P06213; -.
DR   BioGRID; 109854; 185.
DR   CORUM; P06213; -.
DR   DIP; DIP-480N; -.
DR   ELM; P06213; -.
DR   IntAct; P06213; 246.
DR   MINT; P06213; -.
DR   STRING; 9606.ENSP00000303830; -.
DR   BindingDB; P06213; -.
DR   ChEMBL; CHEMBL1981; -.
DR   DrugBank; DB08513; [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID.
DR   DrugBank; DB03909; Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate.
DR   DrugBank; DB05120; AT1391.
DR   DrugBank; DB15399; BMS-754807.
DR   DrugBank; DB12267; Brigatinib.
DR   DrugBank; DB09129; Chromic chloride.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB11564; Insulin argine.
DR   DrugBank; DB01306; Insulin aspart.
DR   DrugBank; DB09456; Insulin beef.
DR   DrugBank; DB09564; Insulin degludec.
DR   DrugBank; DB01307; Insulin detemir.
DR   DrugBank; DB00047; Insulin glargine.
DR   DrugBank; DB01309; Insulin glulisine.
DR   DrugBank; DB00030; Insulin human.
DR   DrugBank; DB00046; Insulin lispro.
DR   DrugBank; DB11567; Insulin peglispro.
DR   DrugBank; DB00071; Insulin pork.
DR   DrugBank; DB11568; Insulin tregopil.
DR   DrugBank; DB16637; KW-2450 free base.
DR   DrugBank; DB06075; Linsitinib.
DR   DrugBank; DB01277; Mecasermin.
DR   DrugBank; DB14751; Mecasermin rinfabate.
DR   DrugBank; DB05115; NN344.
DR   DrugCentral; P06213; -.
DR   GuidetoPHARMACOLOGY; 1800; -.
DR   GlyConnect; 1402; 8 N-Linked glycans (6 sites).
DR   GlyGen; P06213; 22 sites, 8 N-linked glycans (6 sites), 1 O-linked glycan (1 site), 1 Ser glycan (1 site), 3 Thr glycans (2 sites).
DR   iPTMnet; P06213; -.
DR   PhosphoSitePlus; P06213; -.
DR   BioMuta; INSR; -.
DR   DMDM; 308153655; -.
DR   CPTAC; CPTAC-1771; -.
DR   CPTAC; CPTAC-1772; -.
DR   EPD; P06213; -.
DR   jPOST; P06213; -.
DR   MassIVE; P06213; -.
DR   MaxQB; P06213; -.
DR   PaxDb; P06213; -.
DR   PeptideAtlas; P06213; -.
DR   PRIDE; P06213; -.
DR   ProteomicsDB; 51872; -. [P06213-1]
DR   ProteomicsDB; 51873; -. [P06213-2]
DR   ABCD; P06213; 3 sequenced antibodies.
DR   Antibodypedia; 3403; 2183 antibodies from 52 providers.
DR   DNASU; 3643; -.
DR   Ensembl; ENST00000302850.10; ENSP00000303830.4; ENSG00000171105.14. [P06213-1]
DR   Ensembl; ENST00000341500.9; ENSP00000342838.4; ENSG00000171105.14. [P06213-2]
DR   GeneID; 3643; -.
DR   KEGG; hsa:3643; -.
DR   MANE-Select; ENST00000302850.10; ENSP00000303830.4; NM_000208.4; NP_000199.2.
DR   UCSC; uc002mgd.2; human. [P06213-1]
DR   CTD; 3643; -.
DR   DisGeNET; 3643; -.
DR   GeneCards; INSR; -.
DR   GeneReviews; INSR; -.
DR   HGNC; HGNC:6091; INSR.
DR   HPA; ENSG00000171105; Low tissue specificity.
DR   MalaCards; INSR; -.
DR   MIM; 125853; phenotype.
DR   MIM; 147670; gene.
DR   MIM; 246200; phenotype.
DR   MIM; 262190; phenotype.
DR   MIM; 609968; phenotype.
DR   MIM; 610549; phenotype.
DR   neXtProt; NX_P06213; -.
DR   OpenTargets; ENSG00000171105; -.
DR   Orphanet; 263458; Hyperinsulinism due to INSR deficiency.
DR   Orphanet; 2297; Insulin-resistance syndrome type A.
DR   Orphanet; 508; Leprechaunism.
DR   Orphanet; 769; Rabson-Mendenhall syndrome.
DR   PharmGKB; PA202; -.
DR   VEuPathDB; HostDB:ENSG00000171105; -.
DR   eggNOG; KOG4258; Eukaryota.
DR   GeneTree; ENSGT00940000155404; -.
DR   HOGENOM; CLU_000288_166_0_1; -.
DR   InParanoid; P06213; -.
DR   OMA; QYIPDDW; -.
DR   OrthoDB; 1567781at2759; -.
DR   PhylomeDB; P06213; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P06213; -.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-74713; IRS activation.
DR   Reactome; R-HSA-74749; Signal attenuation.
DR   Reactome; R-HSA-74751; Insulin receptor signalling cascade.
DR   Reactome; R-HSA-74752; Signaling by Insulin receptor.
DR   Reactome; R-HSA-77387; Insulin receptor recycling.
DR   SABIO-RK; P06213; -.
DR   SignaLink; P06213; -.
DR   SIGNOR; P06213; -.
DR   BioGRID-ORCS; 3643; 13 hits in 1106 CRISPR screens.
DR   ChiTaRS; INSR; human.
DR   EvolutionaryTrace; P06213; -.
DR   GeneWiki; Insulin_receptor; -.
DR   GenomeRNAi; 3643; -.
DR   Pharos; P06213; Tclin.
DR   PRO; PR:P06213; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P06213; protein.
DR   Bgee; ENSG00000171105; Expressed in buccal mucosa cell and 207 other tissues.
DR   ExpressionAtlas; P06213; baseline and differential.
DR   Genevisible; P06213; HS.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0032590; C:dendrite membrane; ISS:ARUK-UCL.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; ISS:ARUK-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005899; C:insulin receptor complex; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005770; C:late endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0032809; C:neuronal cell body membrane; ISS:ARUK-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0038024; F:cargo receptor activity; ISS:ARUK-UCL.
DR   GO; GO:0005525; F:GTP binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043559; F:insulin binding; IDA:UniProtKB.
DR   GO; GO:0005009; F:insulin receptor activity; IDA:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL.
DR   GO; GO:0031995; F:insulin-like growth factor II binding; IPI:BHF-UCL.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IDA:BHF-UCL.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:CAFA.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL.
DR   GO; GO:0051425; F:PTB domain binding; IPI:UniProtKB.
DR   GO; GO:0005198; F:structural molecule activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0032147; P:activation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0030325; P:adrenal gland development; IEA:Ensembl.
DR   GO; GO:0097242; P:amyloid-beta clearance; ISS:ARUK-UCL.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL.
DR   GO; GO:0097062; P:dendritic spine maintenance; ISS:ARUK-UCL.
DR   GO; GO:0008544; P:epidermis development; IEA:Ensembl.
DR   GO; GO:0031017; P:exocrine pancreas development; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007612; P:learning; TAS:ARUK-UCL.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0030238; P:male sex determination; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; TAS:ARUK-UCL.
DR   GO; GO:1990535; P:neuron projection maintenance; ISS:ARUK-UCL.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0048639; P:positive regulation of developmental growth; IMP:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl.
DR   GO; GO:0046326; P:positive regulation of glucose import; IDA:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; IMP:BHF-UCL.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0051446; P:positive regulation of meiotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IBA:GO_Central.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0043243; P:positive regulation of protein-containing complex disassembly; ISS:ARUK-UCL.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; IDA:CACAO.
DR   GO; GO:0060267; P:positive regulation of respiratory burst; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ARUK-UCL.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; ISS:ARUK-UCL.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:BHF-UCL.
DR   GO; GO:0045995; P:regulation of embryonic development; IMP:BHF-UCL.
DR   GO; GO:2000194; P:regulation of female gonad development; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL.
DR   GO; GO:0046718; P:viral entry into host cell; IMP:BHF-UCL.
DR   CDD; cd00063; FN3; 2.
DR   CDD; cd00064; FU; 1.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR040969; Insulin_TMD.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR036941; Rcpt_L-dom_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF17870; Insulin_TMD; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Carbohydrate metabolism;
KW   Cell membrane; Cleavage on pair of basic residues; Diabetes mellitus;
KW   Direct protein sequencing; Disease variant; Disulfide bond; Endosome;
KW   Glycoprotein; Kinase; Lysosome; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000269|PubMed:2211730,
FT                   ECO:0000269|PubMed:2983222, ECO:0000269|PubMed:8257688"
FT   CHAIN           28..758
FT                   /note="Insulin receptor subunit alpha"
FT                   /id="PRO_0000016687"
FT   CHAIN           763..1382
FT                   /note="Insulin receptor subunit beta"
FT                   /id="PRO_0000016689"
FT   TOPO_DOM        28..758
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TOPO_DOM        763..956
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        957..979
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        980..1382
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          624..726
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          757..842
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          853..947
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1023..1298
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          686..708
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          733..741
FT                   /note="Insulin-binding"
FT   REGION          746..766
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          999
FT                   /note="Important for interaction with IRS1, SHC1 and
FT                   STAT5B"
FT                   /evidence="ECO:0000269|PubMed:9428692"
FT   REGION          1360..1382
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1361..1364
FT                   /note="PIK3R1-binding"
FT   ACT_SITE        1159
FT                   /note="Proton donor/acceptor"
FT                   /evidence="ECO:0000269|PubMed:9312016"
FT   BINDING         1033
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:18278056"
FT   BINDING         1057
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:18278056"
FT   BINDING         1104..1110
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:18278056"
FT   BINDING         1163..1164
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:18278056"
FT   BINDING         1177
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:18278056"
FT   SITE            66
FT                   /note="Insulin-binding"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         400
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         401
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         407
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         992
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         999
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:3166375"
FT   MOD_RES         1011
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         1185
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14690593,
FT                   ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887,
FT                   ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165,
FT                   ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:9312016"
FT   MOD_RES         1189
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14690593,
FT                   ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887,
FT                   ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165,
FT                   ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:9312016"
FT   MOD_RES         1190
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14690593,
FT                   ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887,
FT                   ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165,
FT                   ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:9312016"
FT   MOD_RES         1355
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:3166375"
FT   MOD_RES         1361
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:3166375"
FT   CARBOHYD        43
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16894147,
FT                   ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222"
FT   CARBOHYD        52
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16894147,
FT                   ECO:0000269|PubMed:23302862"
FT   CARBOHYD        105
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        138
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16894147,
FT                   ECO:0000269|PubMed:23302862"
FT   CARBOHYD        242
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16894147,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23302862"
FT   CARBOHYD        282
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16894147,
FT                   ECO:0000269|PubMed:23302862"
FT   CARBOHYD        322
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        364
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16894147"
FT   CARBOHYD        424
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16894147"
FT   CARBOHYD        445
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16894147,
FT                   ECO:0000269|PubMed:19349973"
FT   CARBOHYD        541
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:1472036,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        633
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        651
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        698
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        769
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:2983222"
FT   CARBOHYD        782
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        920
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19349973"
FT   CARBOHYD        933
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        35..53
FT   DISULFID        153..182
FT   DISULFID        186..209
FT   DISULFID        196..215
FT   DISULFID        219..228
FT   DISULFID        223..234
FT   DISULFID        235..243
FT   DISULFID        239..252
FT   DISULFID        255..264
FT   DISULFID        268..280
FT   DISULFID        286..311
FT   DISULFID        293..301
FT   DISULFID        315..328
FT   DISULFID        331..335
FT   DISULFID        339..360
FT   DISULFID        462..495
FT                   /evidence="ECO:0000269|PubMed:1472036"
FT   DISULFID        551
FT                   /note="Interchain"
FT                   /evidence="ECO:0000269|PubMed:1472036"
FT   DISULFID        674..899
FT   DISULFID        825..834
FT   VAR_SEQ         745..756
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:2983222, ECO:0000303|Ref.13"
FT                   /id="VSP_002898"
FT   VARIANT         2
FT                   /note="A -> G (in dbSNP:rs7508518)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:2210055, ECO:0000269|PubMed:2280779,
FT                   ECO:0000269|PubMed:2777789, ECO:0000269|PubMed:2806055,
FT                   ECO:0000269|PubMed:2859121, ECO:0000269|PubMed:2983222,
FT                   ECO:0000269|PubMed:3680248"
FT                   /id="VAR_058395"
FT   VARIANT         42
FT                   /note="N -> K (in RMS; impairs transport to the plasma
FT                   membrane and reduces the affinity to bind insulin;
FT                   dbSNP:rs121913143)"
FT                   /evidence="ECO:0000269|PubMed:2121734,
FT                   ECO:0000269|PubMed:2365819"
FT                   /id="VAR_004079"
FT   VARIANT         55
FT                   /note="V -> A (in LEPRCH; Verona-1; dbSNP:rs121913152)"
FT                   /evidence="ECO:0000269|PubMed:1607067"
FT                   /id="VAR_004080"
FT   VARIANT         56
FT                   /note="I -> T (in LEPRCH; abolishes post-translational
FT                   processing; dbSNP:rs1555689937)"
FT                   /evidence="ECO:0000269|PubMed:24498630"
FT                   /id="VAR_079535"
FT   VARIANT         58
FT                   /note="G -> R (in LEPRCH; Helmond; inhibits processing and
FT                   transport; dbSNP:rs52836744)"
FT                   /evidence="ECO:0000269|PubMed:1730625"
FT                   /id="VAR_004081"
FT   VARIANT         86
FT                   /note="D -> G (in IRAN type A)"
FT                   /evidence="ECO:0000269|PubMed:9175790"
FT                   /id="VAR_015907"
FT   VARIANT         89
FT                   /note="L -> P (in IRAN type A)"
FT                   /evidence="ECO:0000269|PubMed:9175790"
FT                   /id="VAR_015908"
FT   VARIANT         113
FT                   /note="R -> P (in LEPRCH; Atlanta-1; abolishes insulin
FT                   binding; dbSNP:rs121913153)"
FT                   /evidence="ECO:0000269|PubMed:12023989,
FT                   ECO:0000269|PubMed:8419945"
FT                   /id="VAR_004082"
FT   VARIANT         119
FT                   /note="A -> V (in LEPRCH; markedly impairs insulin binding;
FT                   dbSNP:rs1347473020)"
FT                   /evidence="ECO:0000269|PubMed:12023989"
FT                   /id="VAR_015909"
FT   VARIANT         120
FT                   /note="L -> Q (in LEPRCH; inhibits receptor processing)"
FT                   /evidence="ECO:0000269|PubMed:12970295"
FT                   /id="VAR_031518"
FT   VARIANT         146
FT                   /note="I -> M (in LEPRCH; mild; dbSNP:rs121913159)"
FT                   /evidence="ECO:0000269|PubMed:7815442,
FT                   ECO:0000269|PubMed:8326490"
FT                   /id="VAR_015539"
FT   VARIANT         167
FT                   /note="V -> L (in IRAN type A; dbSNP:rs938519025)"
FT                   /evidence="ECO:0000269|PubMed:10733238"
FT                   /id="VAR_015910"
FT   VARIANT         171
FT                   /note="Y -> H (in dbSNP:rs1051692)"
FT                   /evidence="ECO:0000269|PubMed:2859121"
FT                   /id="VAR_058396"
FT   VARIANT         220
FT                   /note="P -> L (in Ins resistance; severe;
FT                   dbSNP:rs749094324)"
FT                   /evidence="ECO:0000269|PubMed:8242067"
FT                   /id="VAR_004083"
FT   VARIANT         228
FT                   /note="C -> R (in a gastric adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041429"
FT   VARIANT         236
FT                   /note="H -> R (in RMS and LEPRCH; Winnipeg; may impair
FT                   receptor processing; dbSNP:rs121913145)"
FT                   /evidence="ECO:0000269|PubMed:17201797,
FT                   ECO:0000269|PubMed:2365819"
FT                   /id="VAR_004084"
FT   VARIANT         256
FT                   /note="R -> C (in RMS; dbSNP:rs781007453)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079536"
FT   VARIANT         260
FT                   /note="L -> P (in LEPRCH; Geldeimalsen; dbSNP:rs121913141)"
FT                   /evidence="ECO:0000269|PubMed:2479553"
FT                   /id="VAR_004085"
FT   VARIANT         279
FT                   /note="R -> C (in IRAN type A; inhibits receptor
FT                   internalization; dbSNP:rs1568470274)"
FT                   /evidence="ECO:0000269|PubMed:12107746"
FT                   /id="VAR_015540"
FT   VARIANT         279
FT                   /note="R -> H (in IRAN type A; interferes with receptor
FT                   processing; dbSNP:rs1329693158)"
FT                   /evidence="ECO:0000269|PubMed:12970295"
FT                   /id="VAR_031519"
FT   VARIANT         280
FT                   /note="C -> Y (in IRAN type A)"
FT                   /evidence="ECO:0000269|PubMed:11260230"
FT                   /id="VAR_015911"
FT   VARIANT         286
FT                   /note="C -> Y (in LEPRCH; abolishes post-translational
FT                   processing)"
FT                   /evidence="ECO:0000269|PubMed:24498630"
FT                   /id="VAR_079537"
FT   VARIANT         301
FT                   /note="C -> Y (in LEPRCH)"
FT                   /evidence="ECO:0000269|PubMed:9703342"
FT                   /id="VAR_015912"
FT   VARIANT         308
FT                   /note="Missing (in LEPRCH; abolishes insulin binding)"
FT                   /evidence="ECO:0000269|PubMed:12023989,
FT                   ECO:0000269|PubMed:7538143, ECO:0000269|PubMed:8636294"
FT                   /id="VAR_015913"
FT   VARIANT         350
FT                   /note="S -> L (in RMS and LEPRCH)"
FT                   /evidence="ECO:0000269|PubMed:12970295,
FT                   ECO:0000269|PubMed:8314008"
FT                   /id="VAR_015914"
FT   VARIANT         362
FT                   /note="Missing (in LEPRCH)"
FT                   /evidence="ECO:0000269|PubMed:12538626"
FT                   /id="VAR_015541"
FT   VARIANT         386
FT                   /note="G -> S (in RMS; may impair receptor processing;
FT                   dbSNP:rs764221583)"
FT                   /evidence="ECO:0000269|PubMed:17201797"
FT                   /id="VAR_031520"
FT   VARIANT         393
FT                   /note="G -> R (in LEPRCH; Verona-1; dbSNP:rs267607184)"
FT                   /evidence="ECO:0000269|PubMed:1607067"
FT                   /id="VAR_004086"
FT   VARIANT         409
FT                   /note="F -> V (in IRAN type A; dbSNP:rs121913142)"
FT                   /evidence="ECO:0000269|PubMed:8388389"
FT                   /id="VAR_004087"
FT   VARIANT         439
FT                   /note="W -> S (in LEPRCH; impairs transport of the receptor
FT                   to the cell surface; dbSNP:rs121913158)"
FT                   /evidence="ECO:0000269|PubMed:8188715"
FT                   /id="VAR_015542"
FT   VARIANT         448
FT                   /note="I -> T (in dbSNP:rs1051691)"
FT                   /evidence="ECO:0000269|PubMed:2859121"
FT                   /id="VAR_015915"
FT   VARIANT         458
FT                   /note="N -> D (in LEPRCH; partially inhibits receptor
FT                   processing and autophosphorylation; strongly impairs ERK
FT                   phosphorylation; induces wild-type levels of IRS-1
FT                   phosphorylation; dbSNP:rs121913160)"
FT                   /evidence="ECO:0000269|PubMed:12970295"
FT                   /id="VAR_031521"
FT   VARIANT         487
FT                   /note="K -> E (in LEPRCH; ARK-1; dbSNP:rs121913136)"
FT                   /evidence="ECO:0000269|PubMed:2834824"
FT                   /id="VAR_004088"
FT   VARIANT         489
FT                   /note="N -> D (in IRAN type A; unknown pathological
FT                   significance; dbSNP:rs1135401742)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079538"
FT   VARIANT         489
FT                   /note="N -> S (in IRAN type A; dbSNP:rs121913147)"
FT                   /evidence="ECO:0000269|PubMed:2365819"
FT                   /id="VAR_004089"
FT   VARIANT         492
FT                   /note="Q -> K"
FT                   /evidence="ECO:0000269|PubMed:2859121"
FT                   /id="VAR_015916"
FT   VARIANT         635
FT                   /note="S -> L (in RMS; decreases post-translational
FT                   processing)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079539"
FT   VARIANT         657
FT                   /note="V -> F (in LEPRCH; impairs post-translational
FT                   processing; dbSNP:rs1135401737)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079540"
FT   VARIANT         659
FT                   /note="W -> R (in LEPRCH; impairs post-translational
FT                   processing)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079541"
FT   VARIANT         695
FT                   /note="Q -> R (in dbSNP:rs55906835)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041430"
FT   VARIANT         762
FT                   /note="R -> S (in IRAN type A; dbSNP:rs121913138)"
FT                   /evidence="ECO:0000269|PubMed:3283938"
FT                   /id="VAR_004090"
FT   VARIANT         811
FT                   /note="G -> S (in dbSNP:rs35045353)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041431"
FT   VARIANT         818
FT                   /note="Y -> C (in LEPRCH; abolishes post-translational
FT                   processing)"
FT                   /evidence="ECO:0000269|PubMed:22768670,
FT                   ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079542"
FT   VARIANT         830
FT                   /note="P -> L (in dbSNP:rs2162771)"
FT                   /id="VAR_055986"
FT   VARIANT         835
FT                   /note="S -> I (in RMS; impairs post-translational
FT                   processing; dbSNP:rs1135401739)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079543"
FT   VARIANT         842
FT                   /note="A -> V (in RMS; decreases post-translational
FT                   processing; dbSNP:rs1135401738)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079544"
FT   VARIANT         858
FT                   /note="T -> A (in NIDDM; dbSNP:rs182552223)"
FT                   /evidence="ECO:0000269|PubMed:7657032"
FT                   /id="VAR_015917"
FT   VARIANT         874
FT                   /note="P -> L (in RMS; impairs post-translational
FT                   processing)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079545"
FT   VARIANT         878
FT                   /note="N -> S (in RMS; impairs post-translational
FT                   processing; dbSNP:rs887190835)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079546"
FT   VARIANT         890..1382
FT                   /note="Missing (in LEPRCH)"
FT                   /evidence="ECO:0000269|PubMed:22768670"
FT                   /id="VAR_079547"
FT   VARIANT         925
FT                   /note="I -> T (in LEPRCH; abolishes post-translational
FT                   processing; abolishes insulin binding; dbSNP:rs1599881881)"
FT                   /evidence="ECO:0000269|PubMed:12023989,
FT                   ECO:0000269|PubMed:28765322"
FT                   /id="VAR_015918"
FT   VARIANT         926
FT                   /note="R -> W (in LEPRCH; markedly impairs insulin
FT                   binding;impairs post-translational processing;
FT                   dbSNP:rs911929963)"
FT                   /evidence="ECO:0000269|PubMed:12023989,
FT                   ECO:0000269|PubMed:28765322"
FT                   /id="VAR_015919"
FT   VARIANT         937
FT                   /note="T -> M (in LEPRCH; impaired receptor processing;
FT                   impairs post-translational processing)"
FT                   /evidence="ECO:0000269|PubMed:28765322,
FT                   ECO:0000269|PubMed:9299395"
FT                   /id="VAR_015920"
FT   VARIANT         997
FT                   /note="P -> T (in RMS; reduces insulin binding)"
FT                   /evidence="ECO:0000269|PubMed:12023989"
FT                   /id="VAR_015921"
FT   VARIANT         999..1382
FT                   /note="Missing (in RMS)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079548"
FT   VARIANT         1012
FT                   /note="V -> M (in dbSNP:rs1799816)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8432414,
FT                   ECO:0000269|PubMed:8458533, ECO:0000269|PubMed:9199575"
FT                   /id="VAR_004091"
FT   VARIANT         1020
FT                   /note="R -> Q (in IRAN type A; dbSNP:rs121913148)"
FT                   /evidence="ECO:0000269|PubMed:2002058"
FT                   /id="VAR_004092"
FT   VARIANT         1023
FT                   /note="I -> F"
FT                   /evidence="ECO:0000269|PubMed:8890729"
FT                   /id="VAR_015922"
FT   VARIANT         1035
FT                   /note="G -> V (in IRAN type A; dbSNP:rs121913135)"
FT                   /evidence="ECO:0000269|PubMed:2544998"
FT                   /id="VAR_004093"
FT   VARIANT         1054
FT                   /note="V -> M (in IRAN type A; unknown pathological
FT                   significance; dbSNP:rs1135401741)"
FT                   /evidence="ECO:0000269|PubMed:28765322"
FT                   /id="VAR_079549"
FT   VARIANT         1055
FT                   /note="A -> V (in IRAN type A; dbSNP:rs1599874183)"
FT                   /evidence="ECO:0000269|PubMed:10733238"
FT                   /id="VAR_015923"
FT   VARIANT         1065
FT                   /note="L -> V (in dbSNP:rs56395521)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041432"
FT   VARIANT         1075
FT                   /note="A -> D (in IRAN type A)"
FT                   /evidence="ECO:0000269|PubMed:8243830"
FT                   /id="VAR_004094"
FT   VARIANT         1095
FT                   /note="K -> E (in a NIDDM subject; dbSNP:rs909008899)"
FT                   /evidence="ECO:0000269|PubMed:2040394"
FT                   /id="VAR_015924"
FT   VARIANT         1119
FT                   /note="R -> W (in LEPRCH; dbSNP:rs1229730671)"
FT                   /evidence="ECO:0000269|PubMed:12970295,
FT                   ECO:0000269|PubMed:9249867"
FT                   /id="VAR_015925"
FT   VARIANT         1143
FT                   /note="I -> T (in RMS; reduces insulin binding)"
FT                   /evidence="ECO:0000269|PubMed:10443650,
FT                   ECO:0000269|PubMed:12023989"
FT                   /id="VAR_015926"
FT   VARIANT         1158
FT                   /note="R -> Q (in NIDDM)"
FT                   /evidence="ECO:0000269|PubMed:1470163"
FT                   /id="VAR_015927"
FT   VARIANT         1158
FT                   /note="R -> W (in RMS; abolishes insulin binding;
FT                   dbSNP:rs111993466)"
FT                   /evidence="ECO:0000269|PubMed:10443650,
FT                   ECO:0000269|PubMed:12023989"
FT                   /id="VAR_015928"
FT   VARIANT         1161
FT                   /note="A -> T (in IRAN type A; dbSNP:rs121913139)"
FT                   /evidence="ECO:0000269|PubMed:2168397"
FT                   /id="VAR_004095"
FT   VARIANT         1162
FT                   /note="A -> E (in IRAN type A; impairs proteolytic
FT                   processing; dbSNP:rs121913154)"
FT                   /evidence="ECO:0000269|PubMed:8096518"
FT                   /id="VAR_004096"
FT   VARIANT         1180
FT                   /note="M -> I (in a patient with insulin resistance;
FT                   dbSNP:rs121913157)"
FT                   /evidence="ECO:0000269|PubMed:1890161"
FT                   /id="VAR_004097"
FT   VARIANT         1191
FT                   /note="R -> Q (in NIDDM; dbSNP:rs121913150)"
FT                   /evidence="ECO:0000269|PubMed:1607076"
FT                   /id="VAR_004098"
FT   VARIANT         1201
FT                   /note="R -> Q (in HHF5 and IRAN type A; interferes with
FT                   kinase activation by insulin; dbSNP:rs121913156)"
FT                   /evidence="ECO:0000269|PubMed:15161766,
FT                   ECO:0000269|PubMed:8082780, ECO:0000269|PubMed:8288049"
FT                   /id="VAR_015929"
FT   VARIANT         1201
FT                   /note="R -> W (in LEPRCH and RMS; reduces insulin binding
FT                   possibly due to reduced receptor levels on the cell
FT                   surface; dbSNP:rs1568426700)"
FT                   /evidence="ECO:0000269|PubMed:12023989,
FT                   ECO:0000269|PubMed:9703342"
FT                   /id="VAR_015930"
FT   VARIANT         1205
FT                   /note="P -> L (in IRAN type A; moderate;
FT                   dbSNP:rs1295645322)"
FT                   /evidence="ECO:0000269|PubMed:1563582,
FT                   ECO:0000269|PubMed:8314008"
FT                   /id="VAR_004099"
FT   VARIANT         1206
FT                   /note="E -> D (in IRAN type A; accelerates degradation of
FT                   the protein and impairs kinase activity)"
FT                   /evidence="ECO:0000269|PubMed:7983039"
FT                   /id="VAR_015931"
FT   VARIANT         1206
FT                   /note="E -> K (in LEPRCH)"
FT                   /evidence="ECO:0000269|PubMed:9249867"
FT                   /id="VAR_015932"
FT   VARIANT         1220
FT                   /note="W -> L (in IRAN type A; accelerates degradation of
FT                   the protein and impairs kinase activity; dbSNP:rs52800171)"
FT                   /evidence="ECO:0000269|PubMed:7983039,
FT                   ECO:0000269|PubMed:8390949"
FT                   /id="VAR_004100"
FT   VARIANT         1227
FT                   /note="W -> S (in IRAN type A; dbSNP:rs121913140)"
FT                   /evidence="ECO:0000269|PubMed:1963473"
FT                   /id="VAR_004101"
FT   VARIANT         1282
FT                   /note="T -> A (in dbSNP:rs55875349)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041433"
FT   VARIANT         1361
FT                   /note="Y -> C (in dbSNP:rs13306449)"
FT                   /evidence="ECO:0000269|PubMed:7657032"
FT                   /id="VAR_015933"
FT   VARIANT         1378
FT                   /note="R -> Q (in IRAN type A; dbSNP:rs52826008)"
FT                   /evidence="ECO:0000269|PubMed:8314008"
FT                   /id="VAR_015934"
FT   MUTAGEN         991
FT                   /note="L->A: Reduces interaction with IRS1 but has no
FT                   effect on interaction with SHC1."
FT                   /evidence="ECO:0000269|PubMed:7559478"
FT   MUTAGEN         992
FT                   /note="Y->A: Reduces interaction with IRS1 but has no
FT                   effect on interaction with SHC1."
FT                   /evidence="ECO:0000269|PubMed:7559478"
FT   MUTAGEN         996..997
FT                   /note="NP->AA: Abolishes interaction with IRS1. Severely
FT                   disrupts, but does not abolish interaction with SHC1."
FT                   /evidence="ECO:0000269|PubMed:7559478"
FT   MUTAGEN         996
FT                   /note="N->A: Abolishes interaction with IRS1 and
FT                   significantly reduces interaction with SHC1. Has no effect
FT                   on interaction with PIK3R1."
FT                   /evidence="ECO:0000269|PubMed:7537849,
FT                   ECO:0000269|PubMed:7559478"
FT   MUTAGEN         997
FT                   /note="P->A: Abolishes interaction with IRS1 and
FT                   significantly reduces interaction with SHC1. Has no effect
FT                   on interaction with PIK3R1."
FT                   /evidence="ECO:0000269|PubMed:7537849,
FT                   ECO:0000269|PubMed:7559478"
FT   MUTAGEN         998
FT                   /note="E->A: Does not affect interaction with IRS1, SHC1 or
FT                   PIK3R1."
FT                   /evidence="ECO:0000269|PubMed:7537849"
FT   MUTAGEN         999
FT                   /note="Y->E: Abolishes interaction with IRS1 and SHC1."
FT                   /evidence="ECO:0000269|PubMed:2842060,
FT                   ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478,
FT                   ECO:0000269|PubMed:9428692"
FT   MUTAGEN         999
FT                   /note="Y->F: Has no effect on insulin-stimulated
FT                   autophosphorylation, but inhibits the biological activity
FT                   of the receptor. Abolishes interaction with IRS1 and almost
FT                   completely prevents interaction with SHC1. Has no effect on
FT                   interaction with PIK3R1. Abolishes interaction with
FT                   STAT5B."
FT                   /evidence="ECO:0000269|PubMed:2842060,
FT                   ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478,
FT                   ECO:0000269|PubMed:9428692"
FT   MUTAGEN         1000
FT                   /note="L->A,R: Severely reduces interaction with SHC1. Has
FT                   no effect on interaction with IRS1."
FT                   /evidence="ECO:0000269|PubMed:7559478"
FT   MUTAGEN         1002
FT                   /note="A->D: Reduces interaction with IRS1 but has no
FT                   effect on interaction with SHC1."
FT                   /evidence="ECO:0000269|PubMed:7559478"
FT   MUTAGEN         1011
FT                   /note="Y->A: Increases kinase activity."
FT                   /evidence="ECO:0000269|PubMed:12707268"
FT   MUTAGEN         1057
FT                   /note="K->A: Abolishes the kinase activity and abolishes
FT                   interaction with IRS1, SHC1, GRB7 and PIK3R1."
FT                   /evidence="ECO:0000269|PubMed:10803466,
FT                   ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849"
FT   MUTAGEN         1057
FT                   /note="K->M,R: Abolishes the kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10803466,
FT                   ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849"
FT   MUTAGEN         1159
FT                   /note="D->N: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11598120"
FT   MUTAGEN         1163
FT                   /note="R->Q: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11598120"
FT   MUTAGEN         1189
FT                   /note="Y->F: Reduced interaction with GRB7."
FT                   /evidence="ECO:0000269|PubMed:10803466"
FT   MUTAGEN         1190
FT                   /note="Y->F: Strongly reduced interaction with GRB7."
FT                   /evidence="ECO:0000269|PubMed:10803466"
FT   CONFLICT        601
FT                   /note="D -> N (in Ref. 19; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        830
FT                   /note="P -> E (in Ref. 19; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1278
FT                   /note="K -> N (in Ref. 2; CAA26096)"
FT                   /evidence="ECO:0000305"
FT   STRAND          33..42
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   HELIX           45..50
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          53..65
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   HELIX           70..72
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   TURN            73..75
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          83..86
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          88..93
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   TURN            100..102
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          103..105
FT                   /evidence="ECO:0007829|PDB:7MQO"
FT   STRAND          115..117
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          118..124
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          141..149
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   HELIX           160..162
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   HELIX           167..169
FT                   /evidence="ECO:0007829|PDB:7KD6"
FT   STRAND          171..175
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   HELIX           176..178
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   TURN            187..192
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          199..201
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          204..206
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          209..211
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   HELIX           221..223
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          230..232
FT                   /evidence="ECO:0007829|PDB:7MQO"
FT   STRAND          243..247
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          251..260
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          263..267
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          273..275
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   TURN            276..278
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          279..281
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   HELIX           283..295
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          298..300
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          305..307
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          310..314
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          319..321
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   TURN            323..325
FT                   /evidence="ECO:0007829|PDB:7KD6"
FT   STRAND          327..330
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          332..334
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          338..348
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   HELIX           351..355
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   TURN            356..359
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          361..369
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          373..375
FT                   /evidence="ECO:0007829|PDB:6HN5"
FT   HELIX           377..385
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          390..393
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          395..399
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          404..406
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   TURN            422..424
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          425..430
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          437..439
FT                   /evidence="ECO:0007829|PDB:4ZXB"
FT   TURN            441..443
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          447..450
FT                   /evidence="ECO:0007829|PDB:6HN5"
FT   STRAND          452..458
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   HELIX           463..472
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   TURN            476..478
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   TURN            481..483
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          486..490
FT                   /evidence="ECO:0007829|PDB:2HR7"
FT   STRAND          498..500
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          502..507
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          512..516
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   HELIX           524..526
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          527..534
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          538..540
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          552..554
FT                   /evidence="ECO:0007829|PDB:6HN5"
FT   STRAND          557..561
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          570..573
FT                   /evidence="ECO:0007829|PDB:6HN5"
FT   STRAND          578..580
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          588..597
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          601..603
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          608..610
FT                   /evidence="ECO:0007829|PDB:4ZXB"
FT   STRAND          613..616
FT                   /evidence="ECO:0007829|PDB:6PXW"
FT   STRAND          626..631
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          633..636
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          638..643
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          654..658
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   HELIX           666..669
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   HELIX           732..740
FT                   /evidence="ECO:0007829|PDB:6VEP"
FT   STRAND          798..803
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          805..809
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          817..827
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          838..843
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          858..861
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          867..870
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          881..890
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          896..901
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   HELIX           902..908
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          910..913
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          918..931
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   STRAND          940..944
FT                   /evidence="ECO:0007829|PDB:6PXV"
FT   HELIX           953..979
FT                   /evidence="ECO:0007829|PDB:2MFR"
FT   STRAND          992..995
FT                   /evidence="ECO:0007829|PDB:5U1M"
FT   TURN            1003..1005
FT                   /evidence="ECO:0007829|PDB:4XLV"
FT   HELIX           1009..1011
FT                   /evidence="ECO:0007829|PDB:1IR3"
FT   HELIX           1014..1016
FT                   /evidence="ECO:0007829|PDB:1IRK"
FT   HELIX           1020..1022
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1023..1031
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1033..1043
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1046..1048
FT                   /evidence="ECO:0007829|PDB:2Z8C"
FT   STRAND          1050..1057
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   HELIX           1065..1078
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1089..1093
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1095..1098
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1100..1104
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   HELIX           1111..1117
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1119..1121
FT                   /evidence="ECO:0007829|PDB:3ETA"
FT   HELIX           1133..1152
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1154..1156
FT                   /evidence="ECO:0007829|PDB:2AUH"
FT   HELIX           1162..1164
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1165..1167
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1173..1175
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1181..1183
FT                   /evidence="ECO:0007829|PDB:1IRK"
FT   TURN            1185..1187
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   STRAND          1190..1192
FT                   /evidence="ECO:0007829|PDB:5HHW"
FT   STRAND          1194..1198
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   HELIX           1200..1202
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   HELIX           1205..1210
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   HELIX           1215..1230
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   TURN            1236..1239
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   HELIX           1242..1250
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   HELIX           1263..1272
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   HELIX           1277..1279
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   HELIX           1283..1290
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   HELIX           1291..1293
FT                   /evidence="ECO:0007829|PDB:5HHW"
FT   HELIX           1298..1301
FT                   /evidence="ECO:0007829|PDB:3BU3"
FT   TURN            1303..1305
FT                   /evidence="ECO:0007829|PDB:4XLV"
FT   HELIX           1307..1309
FT                   /evidence="ECO:0007829|PDB:1I44"
SQ   SEQUENCE   1382 AA;  156333 MW;  709A955660739066 CRC64;
     MATGGRRGAA AAPLLVAVAA LLLGAAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL
     QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL
     VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE
     ECGDICPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHSECL
     GNCSQPDDPT KCVACRNFYL DGRCVETCPP PYYHFQDWRC VNFSFCQDLH HKCKNSRRQG
     CHQYVIHNNK CIPECPSGYT MNSSNLLCTP CLGPCPKVCH LLEGEKTIDS VTSAQELRGC
     TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGYLKIRRS YALVSLSFFR KLRLIRGETL
     EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE
     RNDIALKTNG DQASCENELL KFSYIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ
     NVTEFDGQDA CGSNSWTVVD IDPPLRSNDP KSQNHPGWLM RGLKPWTQYA IFVKTLVTFS
     DERRTYGAKS DIIYVQTDAT NPSVPLDPIS VSNSSSQIIL KWKPPSDPNG NITHYLVFWE
     RQAEDSELFE LDYCLKGLKL PSRTWSPPFE SEDSQKHNQS EYEDSAGECC SCPKTDSQIL
     KELEESSFRK TFEDYLHNVV FVPRKTSSGT GAEDPRPSRK RRSLGDVGNV TVAVPTVAAF
     PNTSSTSVPT SPEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDTP EERCSVAAYV
     SARTMPEAKA DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV
     SRKHFALERG CRLRGLSPGN YSVRIRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG
     PLIFVFLFSV VIGSIYLFLR KRQPDGPLGP LYASSNPEYL SASDVFPCSV YVPDEWEVSR
     EKITLLRELG QGSFGMVYEG NARDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG
     FTCHHVVRLL GVVSKGQPTL VVMELMAHGD LKSYLRSLRP EAENNPGRPP PTLQEMIQMA
     AEIADGMAYL NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV
     RWMAPESLKD GVFTTSSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDQPDN
     CPERVTDLMR MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFHSEENK APESEELEME
     FEDMENVPLD RSSHCQREEA GGRDGGSSLG FKRSYEEHIP YTHMNGGKKN GRILTLPRSN
     PS
//
